87 PostScript - bjo.bmj.com · ated with a poor visual prognosis.5 In a small study CNV was...

PostScript..............................................................................................

LETTERS

Serpiginous choroidopathypresenting as choroidalneovascularisationSerpiginous choroidopathy is an insidious,relentlessly progressive, idiopathic inflamma-tory disease affecting the retinal pigment epi-thelium and inner choroid. Choroidal neovas-cularisation (CNV) is a well recognised latecomplication of serpiginous choroidopathy in10–25% of affected patients.1 In all previouslyreported cases CNV was recognised at thetime of or after the diagnosis of serpiginouschoroidopathy was established.2–4 We report apatient presenting with CNV who subse-quently developed clinical findings character-istic of serpiginous choroidopathy.

Case reportA 31 year old man presented with decreasedvision in his right eye in July 1997. Examina-tion revealed acuities of 20/40 right eye and20/20 left eye with normal anterior segments.The right fundus showed subretinal fluid andhaemorrhage adjacent to the disc (Fig 1A).The left eye showed an irregularity superior tothe optic disc (Fig 1B). The vitreous and fundiwere otherwise normal bilaterally. Fluoresceinangiography (Fig 2A, B) revealed peripapil-lary choroidal neovascular membranes inboth eyes that were treated with argon laserphotocoagulation. In April 1998 and February1999 the left eye required photocoagulationfor recurrent peripapillary CNV. Evaluation for

floaters in February 2000 revealed 1+ vitreouscells and new lesions in the left eye.

Examination at the National Eye Institutein April 2000 revealed acuities of 20/40 righteye and 20/16 left eye with normal anteriorsegments. The vitreous contained trace cellswithout haze bilaterally. The right fundusshowed a large peripapillary chorioretinalscar. The left fundus revealed a chorioretinalscar superior to the disc and two yellow,irregularly circumscribed, deep macular le-sions (Fig 3A, B). The retinal vessels and discswere normal and no subretinal fluid, haemor-rhage, or macular oedema was noted in eithereye.

Fluorescein angiography revealed early hy-pofluorescence and late hyperfluorescencecorresponding to the macular lesions in theleft eye (Fig 3C, D) with no evidence of CNV ineither eye. Laboratory studies were non-diagnostic. A diagnosis of serpiginouschoroidopathy was made based on the clinicaland fluorescein characteristics of the macularlesions in the left eye.

CommentCNV in serpiginous choroidopathy is associ-ated with a poor visual prognosis.5 In a smallstudy CNV was reported to develop within 16months of the serpiginous diagnosis.3 In alarger retrospective study of 53 serpiginouspatients active CNV was found in threepatients at the time of initial diagnosis and inthree others within 2–17 months.4 Our patientdiffers from those previously reported in thathe was diagnosed and treated for idiopathicCNV before the recognition of clinical findings

Figure 1 July 1997. (A) The right eyeshows subretinal fluid adjacent to the discsurrounded by subretinal haemorrhageextending to the fovea. (B) An undefinedirregularity is noted superior to the optic discof the left eye.

Figure 2 (A) Angiography of the right eyereveals a wedge shaped peripapillary CNVmembrane. (B) A smaller CNV membrane ispresent angiographically superior to the leftoptic disc (late phase).

Figure 3 April 2000. (A) The right eye shows a large peripapillary chorioretinal scarresulting from previous laser photocoagulation of the initial CNV lesion. (B) A similarphotocoagulation scar is present in the left eye which also shows two non-contiguous activeserpiginous lesions. The fluorescein angiogram of the left eye shows early hypofluorescence(C, arrows) corresponding to the locations of the active serpiginous lesions that later becomehyperfluorescent (D).

Br J Ophthalmol 2003;87:1184–11971184

www.bjophthalmol.com

on 13 May 2019 by guest. P

rotected by copyright.http://bjo.bm

j.com/

Br J O

phthalmol: first published as 10.1136/bjo.87.9.1192 on 20 A

ugust 2003. Dow

nloaded from

http://bjo.bmj.com/

diagnostic of serpiginous choroidopathy.Other causes of posterior uveitis associatedwith CNV and chorioretinal lesions similar tothose seen in our patient include acute poste-rior multifocal pigmented placoid epithelio-pathy (APMPPE), presumed ocular histo-plasmosis syndrome (POHS), sarcoidosis,multifocal choroiditis, birdshot chorioretin-opathy, and toxoplasmosis. As with most casesof serpiginous choroidopathy, the CNV inthese entities typically occurs late in thedisease course.

The exact pathogenesis of idiopathic CNV isunknown. CNV in eyes with uveitis, however,is believed to develop in direct response to theintraocular inflammation which may alter thebalance between vascular growth factors,such as vascular endothelial growth factor(VEGF), and inhibitors.1 6 In the early stagesof development active serpiginous lesions andCNV may appear as poorly defined subretinallesions difficult to differentiate by ophthal-moscopy. Typically with fluorescein angio-graphy classic CNV and serpiginous lesionsare readily distinguished as the former showsearly hyperfluorescence while the latter char-acteristically shows early blockage. OccultCNV, which may show subtle or less pro-nounced early hyperfluorescence with lateleakage, however, may be more difficult todistinguish from an early serpiginous lesion.

This case illustrates that serpiginouschoroidopathy may present with CNV. Incontrast to idiopathic CNV, optimal treatmentof CNV in patients with uveitis may requireimmunosuppressive treatment that addressesthe underling ocular inflammation with orwithout adjunctive laser therapy.1 6 Furtherinvestigation is needed to better define the roleof emerging therapies for CNV such as photo-dynamic therapy which may offer promise forthe treatment of CNV in uveitis patients.7

Financial support: none.

D K LeeDepartment of Ophthalmology, Jonas FriendenwaldOphthalmic Institute at Maryland General Hospital,

Baltimore, MD, USA

W Augustin, R R Buggage, E B SuhlerLaboratory of Immunology, National Eye Institute,National Institutes of Health, Bethesda, MD, USA

Correspondence to: Ronald R Buggage, MD,National Eye Institute, National Institutes of Health,

Bldg 10, Room 10N112, Bethesda, MD20892–1857, USA; [email protected]

Accepted for publication 30 October 2002

References1 Kuo IC, Cunningham ET Jr. Ocular

neovascularization in patients with uveitis. IntOphthalmol Clin 2000;40:111–26.

2 Jampol LM, Orth D, Daily MJ, et al.Subretinal neovascularization with geographic(serpiginous) choroiditis. Am J Ophthalmol1979;88:683–9.

3 Erkkila H, Laatikainen L. Subretinal and discneovascularization in serpiginous choroiditis.Br J Ophthalmol 1982;66:326–31.

4 Blumenkranz MS, Gass JD, Clarkson JG.Atypical serpiginous choroiditis. ArchOphthalmol 1982;100:1773–5.

5 Erkkila H, Laatikainen L. A follow up study ofserpiginous choroiditis. Acta Ophthalmol1981;59:707–18.

6 Dees C, Arnold JJ, Forrester JV, et al.Immunosuppressive treatment of choroidalneovascularization associated withendogenous posterior uveitis. ArchOphthalmol 1998;116:1456–61.

7 Farah ME, Costa RA, Muccioli C, et al.Photodynamic therapy with verteporfin forsubfoveal choroidal neovascularization inVogt-Koyanagi-Harada syndrome. Am JOphthalmol 2002;124:137–9.

Optic neuritis in anti-GQ1bpositive recurrent Miller FishersyndromeOnly five cases of optic nerve involvement inMiller Fisher syndrome (MFS) have beendocumented in the literature. This report fur-ther confirms that optic neuritis may be seenin anti-GQ1b positive MFS.

Case reportThis 23 year old woman presented with acuteblurry vision, diplopia, and pain with eyemovement. Her visual acuity was 20/20 righteye and 20/200 left eye with a left relativeafferent pupillary defect (RAPD). She had leftred colour desaturation. Her visual field ontangent screen revealed an enlarged left blindspot and a left upper quadrant temporalperipheral field constriction. She had bilateralsixth nerve palsies, nystagmus in all gazes,and left optic disc oedema. After 1 week hervisual acuity improved to 20/20 in both eyes,but her left disc remained oedematous. Shethen developed rapidly progressive gait ataxiato such a degree that she was unable to walk.Dysmmetria and dysdiadochokinesia weremore marked in her left upper extremity. Shehad very mild distal lower extremity weak-ness, absent lower extremity deep tendonreflexes, and bilateral Babinski’s. She also hadtingling in her hands and feet and decreasedlower extremity vibratory sensation. Hermental status was normal throughout her ill-ness. She was not taking any drugs. Amagnetic resonance image (MRI) of the brainand entire spine and MR venogram were allnormal. Her cerebrospinal fluid (CSF) open-ing pressure was 150 mm H2O. Her CSFprotein was elevated at 70 mg/dl, but CSF glu-cose and cell count were normal; CSF VDRL,Gram stain, routine bacterial, viral, and fungalcultures were all negative. No oligoclonalbands were seen on CSF electrophoresis. Hervisual evoked potential (VEP) revealed adelayed left P100 latency at 131 ms and herbrainstem auditory evoked potential (BAEP)was normal. Electromyogram/nerve conduc-tion study (EMG/NCV) study revealed mildlyprolonged median and peroneal F-waves, nor-mal distal motor latencies in her extremitiesand a reduced left median sensory nerveaction potential (SNAP). Anti-GQ1b antibody(162 EIA U (normal = 100) Athena Diagnos-tics, Worcester, MA, USA) and anti-GM1 anti-body (1035 EIA U (normal = 800) AthenaDiagnostics, Worcester, MA, USA) were bothpositive at high titres. Syphilis and Borreliaserology was normal. Antibodies for acetyl-choline receptor, hepatitis A, B, and C;Mycoplasma, Campylobacter jejuni, Lyme, Hu,MaTa, Yo, CV-2, and Ri were all negative. Sedi-mentation rate, ANA, and c-ANCA were allnormal. Serum and urine toxicological screenwere both negative. After 5 days of plas-mapheresis, her anti-GQ1b and anti-GM1antibodies were negative. Her optic discoedema, ocular motor palsies, and nystagmusimmediately resolved, but she continued towalk with assistance. Two months later shehad fully recovered. Six months after herrecovery she developed a similar recurrence ofher neurological symptoms and signs withleft optic disc oedema. Her visual acuity atthat time was 20/20 right eye and 20/100 lefteye. She had a left RAPD and enlarged leftblind spot again, but no extraocular motilitydefects. Her VEP showed a delayed left P100latency at 142 ms and her BAEP was normal.Single fibre EMG of her left frontalis musclerevealed no blocking suggestive of a neuro-muscular transmission defect. HLA-DR2 allele

was positive and HLA-Cw3 allele was nega-tive. Her anti-GQ1b antibody (212 EIA U(normal = 100) Athena Diagnostics, Worces-ter, MA, USA) was elevated again. She under-went plasmapheresis with full recovery inabout 6 months.

CommentIn addition to the classic triad of ophthalmo-plegia, ataxia, and arreflexia,1 visual impair-ment presenting as optic neuritis may be afeature of anti-GQ1b positive recurrent MFS.Only five cases of optic nerve involvement inMFS have been documented in theliterature.2–5 In the two previously reportedcases of visual impairment in MFS, visualevoked potentials were either absent2 orsuggestive of pre-chiasmal and post-chiasmalvisual pathway dysfunction.3 Demyelinatingoptic neuropathies confirmed by VEP werereported in one patient with possible MFS.4

Two other cases of presumed optic neuritiswere associated with anti-GQ1b positiveMFS.5 6 In the patient presented here, hermarkedly decreased visual acuity, pain witheye movement, dyschromatopsia, and opticdisc oedema that resulted in good visualrecovery are all indicative of the diagnosis ofoptic neuritis. Since high concentrations ofGQ1b gangliosides are known to be present inthe human optic nerve and anti-GQ1b anti-bodies can cross the blood-brain barrier,7 theoptic disc oedema in this patient could repre-sent an anti-GQ1b IgM complement mediatedinflammatory demyelination. Furthermore,her ipsilateral delayed P100 latency is consist-ent with a pre-chiasmal demyelinating opticneuropathy.

In addition to her optic neuritis, this patientconcomitantly demonstrated the classic fea-tures of MFS which are the acute onset ofexternal ophthalmoplegia, ataxia of the cer-ebellar type, and the loss of deep tendonreflexes.1 MFS is considered a variant ofGuillain-Barré syndrome (GBS) because somepatients who present with MFS progress toGBS.8 High titres of anti-GQ1b IgG antibodiesare present in 80% to 100% of patients withMFS.8 MFS may be immunologically differen-tiated from GBS by the presence of anti-GQ1band anti-GM1 antibodies. Although bothanti-GD1a IgG and anti-GM1 IgG are associ-ated with GBS,9 anti-GM1 IgG is present inpatients with typical MFS who have limbweakness,9 as in this patient. As furtherevidence linking this antibody to MFS,8 thedecrease in anti-GQ1b antibody levels afterplasmapheresis correlated with the clinicalrecovery in this patient. Therefore, the el-evated titres of anti-GQ1b and anti-GM1antibodies, along with the clinical triad ofophthalmoplegia, arreflexia, and ataxia in thispatient all support the diagnosis of MFS, andnot GBS.

In rare cases, MFS has been known to recur.This patient presented with a relapse of simi-lar clinical features 6 months after recoveryfrom her initial episode. In the study done byChida et al,10 patients with recurrent MFSappeared to have similar HLA typing charac-teristics as the non-recurring ones. Both typesshared HLA-DR2 and Cw3 alleles, but the fre-quency of HLA-DR2 was slightly higher in thepatients with recurrent MFS.10 Therefore, thispatient’s HLA-DR2-positive status may havebeen a risk factor for her recurrence of MFS.

This case report emphasises that optic neu-ritis may be a central nervous system featurethat should be recognised as part of the MillerFisher syndrome. The presence of both anti-GQ1b IgG and anti-GM1 IgG in this patientprovides immunological evidence supportive

PostScript 1185




j.com/

Br J O


ugust 2003. Dow

nloaded from

http://bjo.bmj.com/

of typical MFS. The delayed P100 latency inher VEP also provides electrophysiologicalevidence that the optic nerve is affected inanti-GQ1b antibody positive MFS. Further-more, this is the first documented case knownto the author of optic neuritis in the recurrentsubtype of MFS which is associated with ahigher frequency of the HLA-DR2 allele.

J W ChanDepartment of Internal Medicine, Division ofNeurology, University of Nevada School of

Medicine, 1707 W Charleston Blvd, Suite 220, LasVegas, Nevada 89102, USA; [email protected]

Accepted for publication 6 January 2003

References1 Fisher M. An unusual variant of acute

idiopathic polyneuritis (syndrome ofophthalmoplegia, ataxia and areflexia). NEngl J Med 1956;225:57–65.

2 Ouhabi H, Bourazza A, Rouimi A, et al.[Bilateral optic neuritis andponto-mesencephalic involvement shown byMRI in Miller-Fisher syndrome.] [In Freud] RevNeurol (Paris) 1998;154:780–2.

3 Toshniwal P. Demyelinating optic neuropathywith Miller Fisher syndrome. The case foroverlap syndromes with central and peripheraldemyelination. J Neurol 1987;234:353–8.

4 Carvalho AA, Galvao MD, Rocha MS, et al.Miller Fisher syndrome and optic neuritis: casereport. Arq Neuropsiquiatr 2000;58:1115–7.

5 Colding-Jorgensen E, Vissing J. Visualimpairment in anti-GQ1b positive Miller Fishersyndrome. Acta Neurol Scand2001;103:259–60.

6 Sasaki Y, Takubo H, Arai T, et al. AtypicalFisher syndrome with optic nerve involvement.No To Shinkei 2001;53:571–3.

7 Yoshino H, Maeda Y, King M, et al. Sulfatedglucuronyl glycolipids and gangliosides in theoptic nerve of humans. Neurology1993;43:408–11.

8 Chiba A, Kusunoki S, Shimizu T, et al. SerumIgG antibody to ganglioside GQ1b is apossible marker of Miller Fisher syndrome.Ann Neurol 1992;31:677–9.

9 Kornberg AJ, Pestronk A, Bieser K, et al. Theclinical correlates of high-titer IgG anti-GM1antibodies. Ann Neurol 1994;35:234–7.

10 Chida K, Nomura H, Konno H, et al.Recurrent Miller Fisher syndrome: clinical andlaboratory features and HLA antigens. JNeurol Sci 1999;165:139–43.

Ocular myasthenia gravis andinflammatory bowel disease: acase report and literature reviewMyasthenia gravis has been reported to beassociated with both ulcerative colitis (UC)and Crohn’s disease (CD).1–3 The link betweeninflammatory bowel disease (IBD) andmyasthenia gravis (MG) is thought to berelated to the production of autoantibodies.1

Myasthenia gravis is also associated withother autoimmune diseases including alo-pecia, lichen planus, vitiligo, and systemiclupus erythematosus.4

Similarly, IBD frequently presents withother autoimmune disorders. One study dem-onstrated a 9.4% prevalence of autoimmunedisorders in patients with UC includingsclerosing cholangitis, thyroid disorders, vi-tiligo, insulin dependent diabetes mellitus,thyroid disease, pernicious anaemia, sclero-derma, and seropositive rheumatoidarthritis.4 5 Despite the association betweenMG and other autoimmune disorders, thereare relatively few reports of ocular findings asthe presenting sign of MG in patients withIBD.

Case reportA 21 year old African-American male, with amedical history of biopsy proved ulcerative

colitis diagnosed in 1995, focal segmentalglomerular sclerosis determined by renalbiopsy in 1995, and primary sclerosingcholangitis determined by liver biopsy in 2000presented to the neuro-ophthalmology servicewith complaints of binocular diplopia andptosis of the left upper eyelid. Both the diplo-pia and the ptosis were better in the morningand worsened during the course of the day.His ulcerative colitis had been in remission forthe past 5 years without medication.

Best corrected visual acuity was 20/25 ineach eye. The external examination revealedptosis of the left upper eyelid that worsened insustained upgaze. He had limited extraocularmotility in all fields of gaze (Fig 1). Theremainder of the neuro-ophthalmic examina-tion was normal and he had no difficulty withspeech or swallowing.

Laboratory evaluation revealed a positiveacetylcholine receptor antibody and normalthyroid function studies. There was no evi-dence of a thymic mass on magnetic reso-nance imaging of the chest.

The patient returned to the emergencyroom 1 week later with difficulty swallowingand shortness of breath. He was hospitalisedfor plasmapheresis and upon dischargetreated with imuran, prednisone, and mesti-non. One month later his ptosis resolved andhis extraocular motility was normal.

CommentAutoimmune disorders, including MG, occurmore frequently in UC than in CD.3 It is not

clear how many other cases of IBD manifested

with ocular presentations as the initial finding

of MG as in our case report. Our literature

review revealed only one other purely ocular

presentation of myasthenia associated with

ulcerative colitis; however, details of the

ocular examination were not included.5 An-

other report, of a 21 year old woman with a 3year history of Crohn’s disease, documenteddiplopia and unilateral ptosis as the initialfindings of MG.3 She was found to haveacetylcholine receptor antibodies and herocular findings improved with pyridostig-mine.

Because of the relatively few reports of ocu-lar myasthenia in patients with IBD wereviewed the English literature and foundfour additional reports of MG in patients withIBD. Based on these four reports and the three(including the present report) with ocular MGin patients with IBD (Table 1), the meanduration of IBD before the diagnosis of MGwas 10 years.

Autoimmune dysregulation is the centraldefect in both MG and IBD. Both IBD and MGmay be associated with an elevated carci-noembryonic antigen (CEA) and decreasedperipheral lymphocyte counts that subse-quently normalise following thymectomy.6

Some studies have shown abnormal thymicinvolution and the presence of an abnormalratio of T suppressor to T helper cells in bothMG and UC, while others have noted a declinein suppressor T cells and an increase in

Figure 1 External photograph shows ptosis of the left upper eyelid, restriction of allextraocular movements of the left eye, and an elevation and adduction deficit of the right eye.

Table 1 Previous reports of myasthenia gravis occurring in patients withinflammatory bowel disease

ReferenceAge(years) Sex IBD

Duration of IBDbefore diagnosisof MG (years)

AchR antibodyreactivity

Miller 19715 35 Male UC 13 UnknownTan 19744 38 Male UC 12 UnknownMartin et al, 19911 63 Male CD 15 PositiveGower-Rousseau et al, 19938 27 Female UC 10 PositiveFinnie et al, 19943 21 Female CD 3 PositiveLossos et al, 19959 11 Male CD 9 UnknownPresent report 21 Male UC 7 Positive

IBD = inflammatory bowel disease, MG = myasthenia gravis, AchR = acetylcholine receptor, UC =ulcerative colitis, CD = Crohn’s disease.

1186 PostScript




j.com/

Br J O


ugust 2003. Dow

nloaded from

http://bjo.bmj.com/

immature helper T cells suggesting migrationwithout normal maturation.2 7

The immunological link between MG andIBD is highlighted by two reports of patientsundergoing surgical treatment. One report ofa patient with both MG and CD documentedimprovement in perineal and perianal diseasefollowing thymectomy for severe uncontrolledMG.3 Another patient with both MG and UCdemonstrated regression of the myastheniafollowing proctolectomy.8

Although the simultaneous occurrence ofthese two autoimmune disorders is uncom-mon, it is important to understand that ocularfindings may be the initial manifestation ofMG in patients with IBD.

The authors have no proprietary interest in any con-

tents of this manuscript

R Foroozan, R SamburskyNeuro-Ophthalmology Service, Baylor College of

Medicine, 6565 Fannin, NC-205, Houston,TX 77030, USA

Correspondence to: Dr Rod Foroozan,Neuro-Ophthalmology Service, Baylor College of

Medicine, 6565 Fannin, NC-205, Houston,TX 77030, USA


References1 Martin RW, Shah A. Myasthenia gravis

coexistent with Crohn’s disease. J ClinGasteroenterol 1991;13:112–13.

2 Souadijian JV, Enriquez P, Silverstein MN, etal. The spectrum of disease associated withthymoma. Coincidence or syndrome? ArchIntern Med 1974;134:374–9.

3 Finnie IA, Shields R, Sutton R, et al. Crohn’sdisease and myasthenia gravis: a possiblerole for thymectomy. Gut 1994;35:278–9.

4 Tan RS. Ulcerative colitis, myasthenia gravis,atypical lichen planus, alopecia areata,vitiligo. Proc R Soc Med 1974;67:195–6.

5 Miller TN. Myasthenia gravis, ulcerativecolitis and lichen planus. Proc R Soc Med1971;64:806.

6 Papatestas AE, Kim U, Genkins G, et al. Theassociation of carcinoembryonic antigen andperipheral lymphocytes. Surgery1974;78:343–48.

7 Aiso S, Yoshida T, Watanabe M, et al.Characterization of thymus cells inhyperplastic thymuses in patients withmyasthenia gravis and ulcerative colitis withmonoclonal antibodies. J Clin Lab Immunol1984;13:137–9.

8 Gower-Rousseau C, Reumaux D, Bellard M,et al. Remission of myasthenia gravis afterproctolectomy in a patient with ulcerativecolitis. Am J Gastroenterol 1993;88:1136–8.

9 Lossos A, River Y, Eliakim A, et al.Neurologic aspects of inflammatory boweldisease. Neurology 1995;45(Pt 1):416–21.

Magnetic resonance imagingfindings in malignant melanomaof the lacrimal sacA case of primary malignant melanoma of thelacrimal sac is presented. This is the firstreport of the preoperative magnetic resonanceimaging (MRI) findings of malignantmelanoma of the lacrimal sac.

Case reportA 54 year old Chinese woman was referred toan ophthalmologist complaining of a 6 monthhistory of left sided bloody tears and epistaxis.She had a firm, non-tender left medialcanthal swelling, and syringing revealed leftnasolacrimal duct (NLD) obstruction. Ocularand periorbital examination was otherwisenormal. A dacryocystogram (DCG) demon-strated a filling defect in the lacrimal sac withNLD obstruction.

An ENT opinion was sought, and nasalexamination revealed left sided septal devia-tion, with no obvious cause for the epistaxis.

Computed tomography (CT) of the headand orbits demonstrated a left lacrimal saclesion extending into the NLD with proximaldilation of the duct and no apparent boneerosion (Fig 1A) MRI confirmed the presenceof a lacrimal sac lesion with intermediate sig-nal intensity on T1 and T2 weighted images(Fig 2A, B) The lesion enhanced with intra-venous gadolinium.

An incisional biopsy of the lacrimal sac (Fig1B) under frozen section control, and paraffinsections, confirmed malignant melanoma.

A full medical review, including MRI of thechest and abdomen, and liver function tests,excluded tumour elsewhere. However, ab-dominal MRI and ultrasound revealed aco-incidental polycystic liver.

Three weeks after biopsy, a wide local exci-sion including the medial upper and lowereyelids, dacryocystectomy and medial maxil-lectomy was performed. A tumour, confinedto the sac, and invasion through the medialwall of the upper NLD, into the lateral wall ofthe nose, and apposing nasal septal mucosa,was seen peroperatively and confirmed histo-logically.

She underwent postoperative adjuvant ra-diotherapy (55 grays) and to date, 4 monthslater, remains well.

CommentMalignant melanoma of the lacrimal sac israre accounting for 5% of lacrimal sactumours.1 2 It has an unfavourable prognosiscompared with other causes of lacrimal sactumour, and is considered more aggressivethan cutaneous malignant melanoma.2 3 Re-sponse to treatment is generally poor, with upto 80% of cases recurring within 2 years.

Radiological features of lacrimal sac tu-mours include filling defects on DCG andmass lesions on CT.1–3 However, to the authors’knowledge, this is the first report of the MRIfindings of malignant melanoma of thelacrimal sac.

Owing to the paramagnetic properties ofmelanin, malignant melanoma appears hy-perintense on T1 weighted imaging, andhypointense on T2 weighted imaging.4 Astudy of six mucosal melanomas of the headand neck found that on T1, five lesions werehyperintense and one was isointense.5 On T2,five were of mixed intensity and one was iso-intense. They concluded that hyperintensityon T1 of mucosal melanomas was characteris-tic but not universal.

The majority of malignant lacrimal sactumours are epithelial in origin.3 Imaging fea-tures suggesting malignancy include invasionof bone, rapid growth, and irregular marginswith skin fixation. On MRI, the majority ofepithelial tumours have intermediate signalintensity on T1 and high T2 signal intensity.High tumour cellularity is associated withintermediate to low T2 signal intensity.6

High signal intensity on T1 is not specificfor malignant melanoma. Subacute haemor-rhage caused by the presence of methaemo-globin is more likely and although melanomamay undergo intratumoral haemorrhage,other tumours with a tendency to bleedinclude small cell lung carcinoma, choriocar-cinoma, and renal cell carcinoma metastases.7

Less likely causes include fat containingtumours (lipoma, dermoid, and teratoma)

Figure 1 (A) Coronal CT scandemonstrating a solid mass of the leftlacrimal sac with proximal dilation of thenasolacrimal duct (arrow). (B) Incisionalbiopsy with lacrimal sac opened andmelanoma visible.

Figure 2 (A) T1 weighted sagittal MRIdemonstrating intermediate signal intensitymass lesion of the lacrimal sac and proximalnasolacrimal duct (arrow). (B) T2 weightedaxial MRI demonstrating intermediate signalintensity mass lesion of the left lacrimal sac(arrow).

PostScript 1187




j.com/

Br J O


ugust 2003. Dow

nloaded from

http://bjo.bmj.com/

requiring MRI fat suppression methods,6

paramagnetic material (manganese, iron, andcopper), and very high (non-paramagnetic)intratumoral protein concentration.

MRI has been reported as a useful investi-gative tool in the assessment of lacrimaldisease owing to its ability to delineate softtissues. Intravenous and intracanaliculargadolinium adds useful information on le-sional enhancement and lacrimal apparatusstructure and function.8 The predictive valueof MRI for lacrimal sac melanoma, however,appears to be variable. Hyperintensity on T1relies on the paramagnetic properties ofmelanin, the presence of which is variable inamelanotic melanoma. This is supported byour case, where only moderate T1 hyperinten-sity with contrast enhancement was demon-strated.

K Billing, R Malhotra, D SelvaOculoplastic and Orbital Unit, Department of

Ophthalmology, Royal Adelaide Hospital, TheUniversity of Adelaide, Australia

S Saloniklis, J TaylorMRI Unit, Department of Radiology, Royal Adelaide

Hospital, Adelaide, Australia

S KrishnanDepartment of Otolaryngology, Royal Adelaide

Hospital, Adelaide, Australia

Correspondence to: Dr Dinesh Selva, Oculoplasticand Orbital Clinic, Department of Ophthalmology,Royal Adelaide Hospital, North Terrace, Adelaide,

South Australia 5000;[email protected]


References1 Owens RM, Wax MK, Kostik D, et al.

Malignant melanoma of the lacrimal sac.Otolaryngol Head Neck Surg1995;113:634–40.

2 Pe’er JJ, Stefanyszyn M, Hidayat AA.Nonepithelial tumors of the lacrimal sac. Am JOphthalmol 1994;118:650–8.

3 Stefanyszyn M, Hidayat AA, Pe’er JJ, et al.Lacrimal sac tumors. Ophthalmic PlastReconstr Surg 1994;10:169–84.

4 Kim SH, Han MH, Park SW, et al.Radiologic-pathologic correlation of unusuallingual masses. Part II: Benign and malignanttumors. Korean J Radiol 2001;2:42–51.

5 Yoshioka H, Kamada T, Kandatsu S, et al.MRI of mucosal malignant melanoma of thehead and neck. J Comput Assist Tomogr1998;22:492–7.

6 Stark DD, Bradley WD. Magnetic resonanceimaging. 3rd ed. St Louis: Mosby, 1999.

7 Atlas SW. Magnetic resonance imaging ofthe brain and spine. 3rd ed. Philadelphia:Lippincott Williams and Wilkins, 2002.

8 Goldberg RA, Heinz GW, Chiu L.Gadolinium magnetic resonance imagingdacryocystography. Am J Ophthalmol1993;115:738–41.

Photodynamic therapy forrecurrent myopic choroidalneovascularisation after limitedmacular translocation surgeryLimited macular translocation (LMT) is one ofthe treatment options for subfoveal choroidalneovascularisation (CNV) resulting frompathological myopia.1 The fundamental surgi-cal principle involves the transposition of thefoveal neurosensory retina to a new site withmore healthy underlying retinal pigmentepithelium.1 2 Direct laser photocoagulation isusually employed as an adjunct measure ineradicating the original CNV after the surgery.It has been observed that geometrically

sizeable translocation is a prerequisite for along term surgical success.2 3 The degree oftranslocation is, however, not often predict-able and any ineffective displacement mayrender the subsequent laser photocoagulationextremely difficult or even impossible toperform.2 4 As a result, the recurrent orpersistent CNV intruding the newly relocatedfovea may jeopardise the final visual out-comes. 4 5 Photodynamic therapy (PDT) maybe considered a viable adjunct treatmentoption in such circumstance.

Case reportA 41 year old woman with pathological myo-pia of −11.0 dioptres in both eyes presentedwith a subfoveal CNV and subretinal haemor-rhage in her right eye in July 2000. The bestcorrected visual acuity (BCVA) was 5/200 inher right eye and 20/30 in her left eye. LMTwith superotemporal 6 mm scleral imbrica-tion was performed in July 2000. The opera-tion was uneventful and an inferior displace-ment of the fovea by 600 µm was achieved.The CNV, however, was still located in thevicinity of the juxtafoveal area and thereforelaser photocoagulation, bearing the potentialrisk of late creeping scar, was not suggested.At the 4 months postoperative visit, her leftBCVA was 20/200 and the original CNVbecame more fibrotic with minimal leakageupon fluorescein angiogram. Nevertheless,she came back at 5 months with a return ofmetamorphosia and a drop in her right visionfrom 20/200 to 10/200. Dilated fundus exam-ination showed a tiny patch of submacularhaemorrhage in direct continuity with the oldfibrotic scar (Fig 1A). Fluorescein angiogramof the early phase demonstrated a freshrecurrent CNV budding out from the originalfibrotic CNV and extending to the centre ofthe foveolar avascular zone (Fig 1B). Moder-ate fluorescein leakage could be seen in thelate phase (Fig 1C). Treatments comprisingrevision macular translocation surgery, sub-macular surgery, photodynamic therapy, and

observation had been thoroughly discussedwith the patient. In view of minimal invasive-ness and comparatively better preservation ofsurrounding neurosensory retinal tissue, PDTwas adopted in treating the CNV recurrence.PDT with verteporfin infusion and laser deliv-ery was performed in accordance with thestandard protocol.6 After the treatment, theblood clot in the fovea was gradually reab-sorbed and the vision improved to 20/200 at 3months of follow up. Complete regression ofthe recurrent CNV at the fovea withoutangiographic leakage was documented overthe follow up angiogram at 3 months andsubsequently (Fig 1D). The vision remainedstable at 20/200 in the latest visit at 24 monthsafter the PDT.

CommentIt has been shown that significant visualimprovement may be achieved by LMT for thetreatment of subfoveal CNV associated withage related macular degeneration (AMD) orpathological myopia.1–5 However, the surgicaltechniques are demanding and the potentialcomplications are not unusual. One of the latepostoperative visually important complica-tions is recurrence of the CNV and this is par-tially caused by an ineffective translocation ofthe fovea or a large lesion size of CNV.4 5 Theincidence of persistent or recurrent CNV afterlimited LMT has been reported to be 40% and35% respectively in age related macular trans-location and being 21% and 14% respectivelyin pathological myopia.4 5 Not many treatmentoptions are available once the fovea isinvolved. Viable surgical options includingrepeated LMT, full 360 degree retinotomy MT,or submacular surgery may be considered butthe surgical risk may be inadvertently higherin the redetachment of the neurosensoryretina. PDT induces a selective thrombosis ofthe abnormal CNV and has been proved to bean effective treatment in preventing a signifi-cant loss of vision in patients with CNVsecondary to AMD or pathological myopia.6

Figure 1 Right eye with recurrent myopic CNV after LMT. (A) Fundus photograph of thepatient showing the recurrent part of CNV budding from the original one with haemorrhageinvolving the subfoveal area. (B) Early phase fluorescein (FA), demonstrating the filling ofchoroidal vascular complex with early hyperfluorescence. (C) Late phase FA showing latemoderate fluorescence leakage from the CNV. Photodynamic therapy (PDT) with the size ofthe laser spot as marked was delivered. (D) Late phase FA at 12 months revealing a completeregression of the recurrent CNV and late scar staining of the original CNV.

1188 PostScript




j.com/

Br J O


ugust 2003. Dow

nloaded from

http://bjo.bmj.com/

Its clinical indications and applications areexpanding.7 Its minimal invasiveness andclinical efficacy make it a safer and visuallydesirable supplementary treatment in recur-rent CNV after LMT. In our patient, thecomplete closure of CNV was achieved withconcomitant vision improvement after a sin-gle session of PDT without evidence of recur-rence at 24 months.

Financial interest: Nil.

Financial support: Nil.

W-M Chan, D S C Lam, D T L Liu,T-H Wong, K S C Yuen

Department of Ophthalmology and Visual Sciences,The Chinese University of Hong Kong, Hong Kong

Correspondence to: Dr Wai-Man Chan,Department of Ophthalmology and Visual Sciences,The Chinese University of Hong Kong, Hong KongEye Hospital, 147K Argyle Street, Kowloon, Hong

Kong; [email protected]


References1 Tano Y. Pathologic myopia: where are we

now? Am J Ophthalmol 2002;134:645–60.2 Lewis H, Kaiser PK, Lewis S, et al. Macular

translocation for subfoveal choroidalneovascularization in age-related maculardegeneration: a prospective study. Am JOphthalmol 1999;129:135–46.

3 Fujii GY, Humayun MS, Pieramici DJ, et al.Initial experience of inferior limited maculartranslocation for subfoveal choroidalneovascularization resulting from causes otherthan age-related macular degeneration. Am JOphthalmol 2001;131:90–100.

4 Fujii GY, Humayun MS, Pieramici DJ, et al.Inferior limited macular translocation forsubfoveal choroidal neovascularizationsecondary to age-related maculardegeneration: 1-year visual outcome andrecurrence report. Am J Ophthalmol2002;134:69–74.

5 Hamelin N, Glacet-Bernard A, Brindeau C, etal. Surgical treatment of subfovealneovascularization in myopia: maculartranslocation vs surgical removal. Am JOphthalmol 2002;133:530–6.

6 Treatment of Age-Related MacularDegeneration with Photodynamic Therapy(TAP) Study Group. Photodynamic therapy ofsubfoveal choroidal neovascularization inage-related macular degeneration withverteporfin: two-year results of 2 randomizedclinical trials—TAP Report 2. Arch Ophthalmol2001;119:198–207.

7 Sickenberg M, Schmidt-Erfurth U, Miller JW,et al. A preliminary study of photodynamictherapy using verteporfin for choroidalneovascularization in pathologic myopia,ocular histoplasmosis syndrome, angioidstreaks, and idiopathic causes. ArchOphthalmol 2000;118:327–36.

Acquired Glanzmann’sthrombasthenia causingprolonged bleeding followingphacoemulsificationPhacoemulsification under topical anaesthe-sia using clear corneal incision is not achallenging procedure for the haemostaticsystem. In patients with known bleeding dia-thesis, this may be the procedure of choice toremove cataract. We report a patient who bledcontinuously for 36 hours following phaco-emulsification under topical anaesthesiathrough a clear corneal incision. This wasmanaged by using a topical haemostatic agentthat has not been used in ophthalmic surgerybefore. Extensive haematological evaluationrevealed the underlying cause to be an

acquired form of Glanzmann’s thrombasthe-nia, a very rare condition.1 2

Case reportA 79 year old woman underwent left phaco-emulsification with intraocular lens implanta-tion under topical anaesthesia through a clearcorneal temporal incision. The procedure wasuneventful but she was seen to bleed from theoperated eye in the recovery room. The eyewas patched but the bleeding continued soak-ing the pads. When re-examined 2 hours later,as there was continuous bleeding, the eye waspatched with gentle pressure. Examinationthe next day showed that the bleeding waspersistent. Pressure bandage was reapplied.Examination in the operating theatre con-firmed the conjunctival origin of the bleedingfrom the site where the left handed surgeonheld the conjunctiva during surgery. Cauteri-sation and an attempt to suture the conjunc-tiva were unsuccessful. It was decided that thesafest option was to use a small piece ofoxidised regenerated cellulose (Surgicel,Ethicon) on the bleeding site and patch theeye.

The piece of Surgicel with clotted blood thatwas lying loose on the conjunctiva wasremoved at review 24 hours later. The con-junctival site had stopped bleeding withevidence of altered blood on the surface whereSurgicel had been applied (Fig 1A). At her lastreview 8 weeks later, she was found to have acorrected visual acuity of 6/18 due to pre-existent macular changes secondary to retinaldetachment that was reattached in 1976. Theconjunctiva had healed well (Fig 1B). Thepatient had previously undergone an un-eventful phacoemulsification and intraocularlens implantation in her right eye under sub-Tenon’s anaesthesia.

The patient’s recent medical history wassignificant for recurrent admissions else-where for investigation of severe anaemia fol-lowing gastrointestinal bleeding. Plateletcount and clotting screen had been normal.Angiodysplasia of stomach and duodenumwere treated with laser and angiodysplasia ofcolon was treated by hemicolectomy. Threeepisodes of epistaxis and an episode of vaginalbleeding were managed conservatively. She

had received 60 units of blood transfusion

over a period of 1 year. Interestingly, she had

appendicectomy and multiple dental extrac-

tions elsewhere many years previously with-

out any significant bleeding. She has not been

on any antiplatelet agents or anticoagulants.

There was no family history of bleeding disor-

ders.

A defect in the platelet function was

suspected, as her coagulation screen including

the platelet count was normal. Platelet aggre-

gation tests showed no aggregation against

any agonists other than ristocetin, which is

dependent on platelet glycoprotein Ib. The

platelets showed normal surface levels of

glycoprotein antigens IIbIIIa and Ib. The

patient’s serum showed presence of inhibitory

antibody against glycoprotein IIbIIIa. This led

to a diagnosis of acquired Glanzmann’s

syndrome, an extremely rare condition of

autoimmune thrombasthenia. No underlying

malignant, autoimmune, or lymphoprolifera-

tive disorder had been identified as a cause for

this patient’s acquired Glanzmann’s throm-

basthenia.

CommentThe patient described had uncontrollable

bleeding for 36 hours following a procedure,

which is generally considered safe in patients

with a bleeding disorder. She developed

bleeding from the conjunctival site where the

surgeon grasped the conjunctiva during cer-

tain stages of the procedure. One would

usually not expect any significant bleeding

from this site; however, in a patient with com-

promised haemostasis the bleeding may be

prolonged. Although the bleeding was no

more than a gentle ooze at any point in time it

was persistent enough for 36 hours before the

topical haemostatic material Surgicel had

been put to use. The consequences of an

intraocular bleed may have seriously threat-

ened her sight.3

We are not aware of any reports of the use of

Surgicel in ophthalmic surgery. All reports of

its use are in other fields of surgery.4 5 This

material is supposed to swell up with blood

and form a gelatinous mass that aids in the

formation of clot. It acts as a haemostatic

adjunct. The exact mode of its action in this

patient with antiplatelet antibodies is unclear.

Our experience shows that oxidised regener-

ated cellulose (Surgicel) may have a role in

ophthalmic surgery especially in lacrimal and

orbital surgery, when faced with bleeding that

is difficult to stop. Various cautionary tales

associated with use of Surgicel have been

reported.6–8

Our report suggests that in the presence of

a severe bleeding disorder, clear corneal

phacoemulsification under topical anaesthe-

sia may not be totally safe. When performing

such a procedure in a patient with known

bleeding disorder it may be safe to take all the

necessary precautions in consultation with a

haematologist to avoid a serious bleed that

may be sight and life threatening. There may

be a role for haemostatic agents like Surgicel.

S Dinakaran, M P EdwardsDepartment of Ophthalmology, A-Floor, Royal

Hallamshire Hospital, Sheffield, UK

K K HamptonDepartment of Haematology, Royal Hallamshire

Hospital, Sheffield, UK

Figure 1 (A) Conjunctival site immediatelyafter removal of Surgicel. (B) Healedconjunctival bleeding site.

PostScript 1189




j.com/

Br J O


ugust 2003. Dow

nloaded from

http://bjo.bmj.com/

Correspondence to: S Dinakaran, Department ofOphthalmology, A-Floor, Royal Hallamshire

Hospital, Sheffield, UK; [email protected]


References1 George JN, Caen JP, Nurden AT.

Glanzmann’s thrombasthenia: the spectrum ofclinical disease. Blood 1990;75:1383–95.

2 Greaves M, Pickering C, Porter NR, et al.Acquired Glanzmann’s thrombasthenia. Blood1983;61:209.

3 Saatci AO, Kuvaki B, Oner FH, et al. Bilateralmassive choroidal hemorrhage secondary toGlanzmann’s syndrome. Ophthalmic SurgLasers 2002;33:148–51.

4 Aidonopoulos AP, Papavramidis ST,Goutzamanis GD, et al. A simple and safemethod for preservation of the injured spleen.Injury 1993;24:300–2.

5 Davidson BR, Burnett S, Javed MS, et al.Experimental study of a novel fibrin sealant forachieving haemostasis following partialhepatectomy. Br J Surg 2000;87:790–5.

6 Kothbauer KF, Jallo GI, Siffert J, et al.Foreign body reaction to hemostatic materialsmimicking recurrent brain tumor. Report ofthree cases. J Neurosurg 2001;95:503–6.

7 Young ST, Paulson EK, McCann RL, et al.Appearance of oxidized cellulose (Surgicel)on postoperative CT scans: similarity topostoperative abscess.. Am J Roentgenol1993;160:275–7.

8 Buckley SC, Broome JC. A foreign bodyreaction to Surgicel mimicking an abscess ortumour recurrence. Br J Neurosurg1995;9:561–3.

Propionibacterium acnesendophthalmitis diagnosed bymicrodissection and PCRAlthough Propionibacterium acnes, a Grampositive anaerobic bacillus, is the most com-monly identified cause of delayed onset post-operative endophthalmitis, routine vitreouscultures are frequently inadequate for itsdiagnosis. This case describes the utility of thehistopathological technique of microdissec-tion and polymerase chain reaction (PCR) forthe diagnosis of delayed postoperative endo-phthalmitis.

Case reportA 78 year old man with a history of vitreousfloaters, a coronary bypass, and aortic valvereplacement underwent an uncomplicatedcataract extraction with intraocular lens(IOL) implantation in the right eye. Threemonths later, he developed increasing floatersin the right eye and was diagnosed with vitri-tis unresponsive to corticosteroid treatment.Examination revealed acuities of 20/25 in theright eye and 20/20 in the left with normalintraocular pressures. The right eye wassignificant for no anterior chamber cells orflare, dilated iris vessels, an IOL withoutdeposits, 3+ vitreous cells with trace haze,and peripheral pigmentary degeneration. Theleft eye was normal with the exception oftrace vitreous cells and a choroidal naevus. Adiagnostic vitrectomy was performed in theright eye. A portion of the vitreous specimenwas cultured for fungi, aerobic and anaerobicbacteria, and the remainder was processed forcytopathological examination. All cultures formicro-organisms were negative.

The vitreous supernatant and unstainedcytology slides were sent to the National EyeInstitute for further evaluation. Vitreal analy-sis for interleukin 2 (IL-2), IL-4, IL-6, IL-10,IFN-γ, and TNF-α using ELISA (Endogen,Woburn, MA, USA) revealed undetectablecytokine levels. The vitreous slides were

stained with Giemsa, Gram, and immuno-histochemical stains for T cells, B cells, andmacrophages. Cytopathological examinationshowed clusters of macrophages admixedwith CD4+ and CD8+ T cells and B cells (Fig1A). Gram positive bacilli were seen in thecytoplasm of a few macrophages (Fig 1B). Theengulfed bacilli were microdissected under amicroscope with a 30 gauge needle andsubmitted for PCR.1 Nested PCR with P acnesspecific oligodeoxynucleotide primers com-plementary to regions of 16S rDNA wasused.2 The primers were Pa1, AAG GCC CTGCTT TTG TGG; rPa2, TCC ATC CGC AAC CGCCGA A; and rPa3, ACT CAC GCT TCG TCACAG. Nested-PCR analysis revealed P acnes(Fig 2). A diagnosis of delayed postoperativeendophthalmitis was made.

CommentThe most common causes of vitritis in elderlypatients are acquired or postoperative infec-tions, sarcoidosis, and intraocular malig-nancies masquerading as uveitis.3 An earlydiagnostic procedure is indicated if postopera-tive endophthalmitis is suspected. In thiscase, although the chronic inflammation andintracytoplasmic Gram positive bacilli in a fewmacrophages suggested an infectious process,the negative cultures precluded the diagnosisof an infectious endophthalmitis. To furtherinvestigate the possibility of a bacterial infec-tion nested PCR was performed on the micro-

dissected bacilli.1 Molecular analysis verifiedthe presence of P acnes and a diagnosis ofdelayed postoperative endophthalmitis wasconfirmed.

Vitreous cultures are positive in less than50% of postoperative endophthalmitis cases.In a study of 25 patients with delayed onsetendophthalmitis aqueous culture and micros-copy were diagnostic in 0% of cases, vitreousculture was positive in 24% and PCR from theaqueous and vitreous yielded a positivediagnosis in 84% and 92%, respectively.4

Treatment of P acnes endophthalmitis includesintravitreal vancomycin plus consideration ofpars plana vitrectomy with or without cap-sulectomy with or without IOL removal.Although aggressive surgical interventioneradicates the infection similar visual out-comes are reported with more limited surgicaltreatment.5

In our case the intracytoplasmic bacteria inthe macrophages were the only evidence of abacterial infection. To detect the presence of Pacnes we referenced the PCR method describedby Hykin that used 150 µl of the vitreous forculture and 100 µl for PCR.2 Using thetechnique of microdissection and PCR with asimilar volume of vitreous we additionallyperformed cytology and cytokine analysiswhich are helpful in the diagnosis of othercauses of vitritis.6

This case further illustrates the benefits ofmolecular analysis for the diagnosis of culture

Figure 1 (A) Photomicrograph of the vitreous specimen showing clusters of macrophagesadmixed with T and B lymphocytes. Many degenerated lymphocytes were also present.(Giemsa, ×200). (B) Higher power photomicrograph of the vitreous specimen showing Grampositive pleomorphic bacilli (arrow) in the cytoplasm of a few macrophages (Gram stain,×640).

Figure 2 Nested PCR products of the microdissected bacilli from the vitreous specimen. Thefirst round used Pa1 and rPa2. The second round used Pa1 and rPa3. The negative control inboth rounds contained no DNA. The positive control in both rounds was P acnes.

1190 PostScript




j.com/

Br J O


ugust 2003. Dow

nloaded from

http://bjo.bmj.com/

negative delayed onset endophthalmitis. Italso describes for the first time microdissec-tion and PCR for the evaluation of endoph-thalmitis. Advantages of this technique arethat it allows for a more comprehensivepathological examination on a limited speci-men and provides the option of having themolecular studies being performed elsewhere.

R R Buggage, D F Shen, C-C ChanLaboratory of Immunology, National Eye Institute,National Institutes of Health, Bethesda, MD, USA

D G CallananTexas Retina Associates, Arlington, TX, USA

Correspondence to: Ronald R Buggage, MD,NIH/NEI, Building 10, Room 10N112, Bethesda,

MD 20892-1857, USA; [email protected]


References1 Zhuang Z, Bertheau P, Emmert-Buck MR, et

al. A microdissection technique for archivalDNA analysis of specific cell populations inlesions <1 mm in size. Am J Pathol1995;93:10595–9.

2 Hykin PG, Tobal K, McIntyre G, et al. Thediagnosis of delayed post-operativeendophthalmitis by polymerase chain reactionof bacterial DNA in vitreous samples. J MedMicrobiol 1994;40:408–15.

3 Berrocal AM, Davis JL. Uveitis followingintraocular surgery. Ophthalmol Clin NorthAm 2002;15:357–64.

4 Lohmann CP, Linde HJ, Reischl U. Improveddetection of microorganisms by polymerasechain reaction in delayed endophthalmitisafter cataract surgery. Ophthalmology2000;107:1047–51; discussion 1051–2.

5 Aldave AJ, Stein JD, Deramo VA, et al.Treatments strategies for postoperativePropionibacterium acnes endophthalmitis.Ophthalmology 1999;106:2395–401.

6 Buggage RR, Whitcup SM, Nussenblatt RB,et al. Using interleukin 10 to interleukin 6 ratioto distinguish primary intraocular lymphomaand uveitis. Invest Ophthalmol Vis Sci1999;40:2462–3.

Interferon treatment ofchildhood conjunctivallymphomaMucosa associated lymphoid tissue (MALT)lymphoma is the most common ocular adn-exal lymphoid proliferation. These neoplasticlesions have a more indolent course thannon-MALT lymphomas, are usually found inthe older age groups (50–70 years), areusually limited to localised (stage I) disease atpresentation, and radiotherapy and chemo-therapy have been the mainstay oftreatment.1

Case reportA 15 year old male was referred by anophthalmologist after an 8 month history ofunusual painless follicles at both nasal for-nices (Fig 1A). There were no visual symp-toms and, based on a working diagnosis of anatypical vernal reaction, topical steroid treat-ment had resulted in mild size reduction ofthe lesions. Incisional biopsy was performedafter the lesions remained static for 3–4months.

The patient’s visual acuity was 6/4 in botheyes and intraocular pressures measured 15mm Hg in each eye. Slit lamp examinationdemonstrated small follicular deposits in bothnasal fornices and nasal palpebral conjunc-tiva. The rest of the ocular examination wasunremarkable. Review of systems was nega-tive and the patient’s past medical history andfamily medical history did not reveal the

presence of lymphoproliferative or auto-immune diseases. There were no findingssuggestive of Sjögren’s syndrome and physicalexamination was normal.

The limited amount of biopsy tissue wasdivided for routine processing and flowcytometry; frozen tissue was therefore un-available. Histologically a dense lymphoidinfiltrate including benign appearing lym-phoid follicles was identified (Fig 1B). Lym-phoid follicles were surrounded bycentrocytic-like cells and small lymphocytes,some of which infiltrated the conjunctivalepithelium. Flow cytometry identified amonoclonal B cell population with a CD5−,CD20+, CD10 equivocal phenotype. The his-topathological findings in isolation may haverepresented either an early marginal zonelymphoma or a benign B cell follicular hyper-plasia. Absolute distinction on the smallamount of tissue was not possible. However,in conjunction with the flow cytometric find-ing of a monoclonal B cell population, a diag-nosis of low grade B cell lymphoma (probablyof MALT type) could be made.

Systemic disease was excluded after thefollowing investigations: lumbar puncture;bone marrow aspirate and trephine; CT chest,abdomen, pelvis and sinuses; gallium scan.The patient was subsequently treated with 10intralesional injections of 10 × 106 IU of inter-feron alfa (IFN-α) over a 4 week period; noside effects were noted during this time. Com-plete resolution was achieved at 2 months,with no sign of recurrence after 18 months’follow up.

CommentConjunctival lymphoma is mostly a disease ofthe elderly, with Shields et al reporting a meanage of diagnosis of 61 years.2 While not acommon disease, Akpek et al suggest that itsprevalence is higher than previously recog-nised, and that vigilance is required inpatients with chronic ocular irritation andconjunctivitis who do not respond to conven-tional therapy.3 This is the youngest case ofconjunctival lymphoma that we know of inthe literature; hence conjunctival lymphoma

should be considered in the differential diag-nosis of atypical conjunctival lesions inyounger patients.

Treatments outlined by Shields et al in-cluded radiotherapy (44%), complete exci-sional biopsy (36%), observation (9%),chemotherapy (6%), and cryotherapy (4%).2

Radiotherapy has been widely used withsuccessful results3–6 but ocular morbidity inthe form of corneal ulcer, radiation inducedcataract and ocular lubrication disorders havebeen reported.4 7 Intralesional IFN-α is a rela-tively new therapy which has been shown tobe both effective and safe in a small number ofcases.1 5 8 9 Non-sight threatening ocular com-plications such as subconjunctival haemor-rhage and local chemosis have been reported,as well as minor transient systemic effectsincluding headaches, nausea, fevers, chills,and myalgia.5 Administration of intralesionalIFN-α is also a relatively simple and quickprocedure. It shows great promise as a firstline agent to treat conjunctival lymphoma,but long term follow up is needed.

R S LucasDepartment of Ophthalmology, Royal BrisbaneHospital, Herston, Queensland 4029, Australia

R MortimoreQueensland Medical Laboratory Consulting

Pathologists, 60 Ferry Road, West End,Queensland 4101, Australia

T J SullivanDepartment of Ophthalmology, Royal BrisbaneHospital, Herston, Queensland 4029, Australia

M WaldieDepartment of Ophthalmology, Royal BrisbaneHospital, Herston, Queensland 4029, Australia

Correspondence to: Associate Professor TimothyJohn Sullivan, Eyelid, Lacrimal and Orbital Clinic,

Department of Ophthalmology, Royal BrisbaneHospital, Herston, Queensland 4029, Australia;

[email protected]


References1 Blasi MA, Gherlinzoni F, Calvisi G, et al.

Local chemotherapy with interferon-α forconjunctival mucosa-associated lymphoidtissue lymphoma. Ophthalmology2001;108:559–62.

2 Shields CL, Shields JA, Carvalho C, et al.Conjunctival lymphoid tumours. Clinicalanalysis of 117 cases and relationship tosystemic lymphoma. Ophthalmology2001;108:979–84.

3 Akpek EK, Polcharoen W, Ferry JA, et al.Conjunctival lymphoma masquerading aschronic conjunctivitis. Ophthalmology1999;106:757–60.

4 Heuring AH, Franke FE, Hütz WW.Conjunctival CD5+ MALT lymphoma. Br JOphthalmol 2001;85:498–9.

5 Cahill MT, Moriarty PA, Kennedy SM.Conjunctival “MALToma” with systemicrecurrence. Arch Ophthalmol 1998;116:97–9.

6 Scullica L, Manganelli C, Turco S, et al.Bilateral non-Hodgkin lymphoma of theconjunctiva. Eye 1999; 13:379–80.

7 Bessel EM, Henk JM, Whitelocke JF, et al.Ocular morbidity after radiotherapy of orbitaland conjunctival lymphoma. Eye1987;1:90–6.

8 Lachapelle KR, Rathee R, Kratky V, et al.Treatment of conjunctival mucosa-associatedlymphoid tissue lymphoma with intralesionalinjection of interferon alfa-2b. ArchOphthalmol 2000;118:284–5.

9 Cellini M, Possati GL, Puddu P, et al.Interferon alpha in the therapy of conjunctivallymphoma in an HIV+ patient. Eur JOphthalmol 1996;6:475–7.

Figure 1 (A) Conjunctival MALTlymphoma, nasal fornix of left eye. (B)Histological section of conjunctival mucosademonstrating dense lymphoid infiltrate(haematoxylin and eosin, originalmagnification ×200).

PostScript 1191




j.com/

Br J O


ugust 2003. Dow

nloaded from

http://bjo.bmj.com/

Unilateral corneal anaesthesiaand ulceration following squintsurgery in a child with Pendredsyndrome and bilateral sixthnerve palsyWe present a 4 year old child with Pendredsyndrome and bilateral sixth nerve palsy. Toour knowledge this association has not beenpreviously reported. In addition, this patientdeveloped unilateral corneal ulceration withassociated corneal anaesthesia followingsquint surgery. We will discuss the patho-physiology of this unusual complication fol-lowing squint surgery.

Case reportThis patient presented when he was 6 monthsold with right convergent squint. He wasdiagnosed with Pendred syndrome (sen-sorineural hearing loss and thyroid dysfunc-tion) by the paediatricians and the otolaryn-gologists following abnormal thyroid functiontests and a computed tomograph (CT) scan ofthe temporal bones showing Mondini malfor-mations of both cochleas. At presentation hisvisual acuities were 6/60 right eye and 6/36left eye using the Cardiff acuity cards. He hadbilateral alternating esotropia with an inabil-ity to abduct either eye. There was no globeretraction or abnormal lid movements and amagnetic resonance imaging (MRI) scan hadshown congenital absence of the auditorynerves but no other abnormality. A diagnosisof bilateral sixth nerve palsy was made. Thesquint was cosmetically poor and measured at45 prism dioptres in the distance and near. Hehad low hypermetropia with no significantanisometropia. Funduscopy was normal. Hewas reviewed regularly in the paediatric eyeclinic over the next 3 years during which timehis visual acuities were within normal limits,the best recorded acuity being 6/9 right eyeand 6/9 left eye using singles.

When he was 4 years old, he underwentbilateral superior rectus and inferior rectuslateral transpositions under general anaesthe-sia, which was uneventful with no immediatepostoperative complications, and a cosmeti-cally acceptable alternating convergent squintof 15 prism dioptres for distance and near.

Two months later he developed a leftinferior corneal ulcer (Fig 1) with surround-ing punctate epitheliopathy which surpris-ingly did not seem to cause him as much dis-tress as expected. The left corneal sensationwas definitely reduced compared to the rightwhich appeared normal. Sensation was as-sessed clinically (an anaesthesiometer wasnot available), and was consistently reproduc-ible by different ophthalmologists. There wasno exophthalmos or any other sign of thyroidorbitopathy. The right eye remained asympto-matic. Empirical therapy with topical

ofloxacin and lubricants was unhelpful. Heproceeded to have glue tarsorrhaphy whichtransiently aided the healing of the cornealulcer. However, the ulcer quickly recurredwhen the tarsorrhaphy reversed. He subse-quently had left inferior lid shortening with acanthal sling to elevate the lower lid to protectthe corneal epithelium. The ulcer resolvedleaving an area of corneal scarring. He is beingreviewed regularly in the eye clinic.

CommentPendred syndrome is an autosomal recessivedisorder characterised by congenital deafnessand thyroid goitre. The hearing loss is usuallysevere and is present at birth, and the goitregenerally appears at puberty or later but maybe present in early childhood with an associ-ated euthyroid or hypothyroid state.1–4 Af-fected individuals are reported to be other-wise normal.

The pathophysiology of the corneal anaes-thesia and ulceration in this patient is uncer-tain. There are several possible reasons for thecorneal anaesthesia. They include herpes sim-plex keratitis, postoperative anterior segmentischaemia, surgical trauma to the long poste-rior ciliary nerves or ciliary ganglion, congeni-tal absence of sensation, and surgery reducingBell’s phenomenon.

The clinical course was not typical of herpessimplex and there was no previous history ofcorneal pathology. Postoperative anterior is-chaemic syndrome was unlikely as only tworecti muscles were operated on and noanterior uveitis was observed. To our knowl-edge there are no reported cases of cornealanaesthesia after squint surgery. There was noevidence of pupillary involvement, which onemay expect with trauma to the long posteriorciliary nerves or ciliary ganglion.

Congenital absence of corneal sensationwas the most likely cause, especially in view ofhis unusual cranial nerve anomalies, and webelieve he had pre-existing corneal anaesthe-sia before squint surgery despite the absenceof any other fifth cranial nerve signs. Follow-ing the lateral transposition of the superiorrectus his Bell’s phenomenon was noted to beabsent thereby compromising his cornealprotection. In addition, he was observed tohave significant lagophthalmos while asleep.We believe that the combination of cornealanaesthesia, abolished Bell’s phenomenon,and lagophthalmos compromised his cornealintegrity resulting in corneal ulceration.

This case highlights the importance ofdetermining corneal sensation before trans-position surgery on the superior rectus asBell’s phenomenon may be abolished there-fore compromising corneal protection. This isespecially relevant in patients with unusualcranial neuropathy and lagophthalmos.

R V WintleEye Unit, Southampton General Hospital, Tremona

Road, Southampton SO22 5DS, UK

Y F ChoongEye Unit, University Hospital of Wales, Cardiff, UK

D E LawsDepartment of Ophthalmology, Singleton Hospital,

Swansea, UK

Correspondence to: Mr Richard V Wintle, Eye Unit,Southampton General Hospital, Tremona Road,

Southampton SO22 5DS, UK;[email protected]

Accepted for publication 16 February 2003

References1 Pendred V. Deaf mutism and goitre. Lancet

1896;11:532.

2 Reardon W, Trembath RC. Pendredsyndrome. J Med Genet 1996;33:1037–40.

3 Reardon W, Coffey R, Phelps PD, et al.Pendred syndrome—100 years ofunderascertainment? Q J Med1997;90:443–7.

4 Fraser GR. Association of congenitaldeafness with goitre (Pendred’s syndrome): astudy of 207 families. Ann Hum Genet1965;28:201–49.

Gemella haemolysans acutepostoperative endophthalmitisEndophthalmitis is perhaps the most fearedcomplication of cataract surgery, with areported incidence between 0.07% and0.13%.1 2 The most common organisms re-ported in previous studies are Gram positivestaphylococci and streptococci.3 4 We report acase of severe endophthalmitis with anunusual Gram positive organism, after un-complicated phacoemulsification, with fold-able intraocular lens implantation.

Case reportA 66 year old white man underwent routinephacoemulsification cataract extraction withposterior chamber lens implantation (Acrylic,Model Hydroview H60M, Bausch & Lomb) tothe right eye in January 2002.

The left eye had previously undergonesimilar surgery in September 2001. He wasgenerally in good health, and on no medi-cation. There was a past medical history ofsarcoidosis treated with oral prednisolone in1970, which has since been in remission, andan episode of staphylococcal septicaemia in1987, without sequelae.

On the first postoperative day, visual acuitymeasured 6/9 unaided and ocular examina-tion was unremarkable. That same afternoonthe patient developed ocular pain, initiallyrelieved by paracetamol (acetaminophen),which however, worsened during the nightwith progressive deterioration of vision. Hepresented to the ophthalmic emergency de-partment the following morning with theaforementioned symptoms. Visual acuity wasreduced to hand movements right eye and 6/9left eye. Slit lamp examination revealed anoedematous cornea with Descemet’s folds.The anterior chamber was hazy, with 1 mmhypopyon and the intraocular pressuremeasured 38 mm Hg.

There was no red reflex. B-scan ultrasoundexamination showed extensive vitreous debriswith attached retina. The left eye was pseudo-phakic with no abnormalities of note. A diag-nosis of acute postoperative endophthalmitiswas made. Anterior chamber and vitreoussamples were obtained for aerobic andanaerobic culture/sensitivity and Gram stain-ing. Intravitreal vancomycin 2 mg and ami-kacin 300 µg, each in 0.1 ml of balanced saltsolution and subconjunctival cefuroxime 125mg were administered. Oral ciprofloxacin 500mg twice daily, prednisolone 60 mg once aday, topical gentamicin hourly, ofloxacinhourly, and atropine 1% twice a day werecommenced.

Preliminary Gram staining suggested aGram positive coccus, sensitive tociprofloxacin—oral and topical antibioticswere therefore continued. Owing to difficultyin identifying the nature of the organism, thesamples were sent to a regional referencelaboratory, which identified Gemella haemoly-sans from both anterior chamber and vitreousaspirates. The organism was reported to besensitive to gentamicin, ciprofloxacin, laevo-floxacin, amoxicillin/clavulanate, chloromyc-etin, and resistant to trimethoprim.

Figure 1 Inferior corneal ulcer beforetreatment.

1192 PostScript




j.com/

Br J O


ugust 2003. Dow

nloaded from

http://bjo.bmj.com/

The patient continued to make steadyprogress; 2 months later vision had improvedto 6/9 unaided. The patient at that time wastroubled by floaters secondary to considerablevitreous debris. At last review in September2002, visual acuity had further improved to6/4 with −0.75DSph correction.

CommentGemella haemolysans is an aerobic or faculta-tive anaerobic, Gram positive coccus, a normalcommensal of the oral cavity and upper respi-ratory tract of low virulence.5 6 Systemicinfection may lead to septic shock, meningitis,arthritis, or pneumonia, all of which are rare.Identification is difficult. Though Gram posi-tive, the cocci are easily decolorised and hencemay appear Gram variable or even negative.

Initially Gemella was included under thegenus Neisseria but is now classified as aseparate genus within the familyStreptococcacea.7 No studies on susceptibilityto antiseptics have been published, thoughthere is no reason to believe that it may beresistant to povidone-iodine preparations. Theorganism is susceptible in vitro to penicillin,streptomycin, vancomycin, chloramphenicol,and tetrasulphathiazole.

A literature search revealed only one previ-ously reported case of infection by Gemellahaemolysans, with keratitis and consecutiveendophthalmitis.6 Interestingly this patientwas reported to have active sarcoidosis onsystemic steroid therapy, whereas our patienthad a past history of sarcoidosis. This possibleassociation between sarcoidosis and infectionby Gemella may be purely coincidental, as nosuch association has been reported withsystemic infection.

Gemella haemolysans is difficult to identify,because of its close resemblance to viridansstreptococcus and Neisseria. As diagnostictechnology improves, Gemella haemolysans en-dophthalmitis may be described more often inthe future. This report highlights the import-ance of infection with rare commensal organ-isms in healthy, immunocompetent individu-als after uneventful phacoemulsificationcataract surgery.

S V Raman, N Evans, T J FreegardRoyal Eye Infirmary, Apsley Road, Plymouth, UK

R CunninghamDepartment of Microbiology, Derriford Hospital,

Plymouth, UK

Correspondence to: S V Raman, West of EnglandEye Unit, Royal Devon and Exeter Hospital, Exeter,

UK; [email protected]

Accepted for publication 25 February 2003

References1 Aaberg TM Jr, Flynn HW Jr, Schiffman J,

et al. Nosocomial acute-onset postoperativesurvey; a ten-year review of incidence andoutcomes. Ophthalmology 1998;105:1004–10.

2 Javitt JC, Vitale S, Canner JK, et al. Nationaloutcomes of cataract extraction;endophthalmitis following inpatient surgery.Arch Ophthalmol 1991;109:1085–9.

3 Shrader KS, Band JD, Lauter CB, et al. Theclinical spectrum of endophthalmitis;incidence, predisposing factors, and featuresinfluencing outcome. J Infect Dis1990;162:115–20.

4 The Endophthalmitis Vitrectomy StudyGroup. Results of the endophthalmitisvitrectomy study; a randomised trial ofimmediate vitrectomy and of intravenousantibiotics for the treatment of postoperativebacterial endophthalmitis. Arch Ophthalmol1995,113;1479–96.

5 Fresard A, Michael VP, Rueda X, et al.Gemella haemolysans endocarditis. Clin InfectDis 1993;16;586–7.

6 Ritterband D, Shah M, Kresloff M, et al.Gemella haemolysan keratitis and consecutiveendophthalmitis. Am J Ophthalmol2002;133:268–9.

7 Klipper-Balz R, Schleifer KH. Transfer ofStreptococcus morbillorum to the Gemellagenus, Gemella morbillorum comb nov. Int JSyst Bacteriol 1988;38:442–3.

Does topical brimonidinetartrate help NAION?There is no proved treatment for non-arteriticanterior ischaemic optic neuropathy(NAION). Topical brimonidine tartrate hasbeen reported to have a neuroprotectivebenefit for retinal ganglion cells followingexperimental elevation of intraocular pressureand optic nerve injury in the rat, which isblocked with coadministration of the α-2antagonist, rauwalscine.1–3 Increased retinalganglion cell survival has also been shown tooccur following oral administration of brimo-nidine in monkeys with experimentalglaucoma.4 These results were the basis of therecently aborted clinical trial of topical brimo-nidine purite for acute NAION and our retro-spective study of 31 patients with NAION,who were evaluated within 3 weeks of theonset of visual loss and had follow up for aminimum of 8 weeks. During 2001–2, wetreated all (14) patients with brimonidinetartrate within 14 days (mean 5.5, SD 5.52) ofthe onset of visual loss. Five patients weretreated after 1 day of symptoms. The dropswere taken four times a day in 11, three timesa day in one, and twice a day in two patients.All (17) untreated patients were evaluated theyear before and were matched to the treatedgroup for age, sex, cardiovascular risk factors,previous aspirin use, and previous first eyeNAION.

Snellen visual acuity and colour vision,using the Ishihara colour plates, were docu-mented and expressed as a decimal equivalent(for acuity: 20/60 = 0.33 and light perception= 0.001; for colour vision: the number of cor-rectly identified plates/the total number ofplates). The visual fields (Humphrey ortangent perimetry) were analysed and defectswere graded according to the following scale:0 = normal, 1 = arcuate nerve fibre bundledefects, 2 = relative central (<6 degrees),caecocentral or altitudinal defects, 3 = altitu-dinal defect plus additional loss, 4 = no lightperception. A third examiner, who was un-aware of the dates of the visual fields and thepatients’ treatment status, also evaluated allvisual fields and determined, in each patient,whether the field was better or worse than orequivalent to the other field. The intraocularpressure was normal in all except twopatients. The pressure was 23 mm Hg in onepatient in the treated group and 24 mm Hg inone patient in the untreated group.

Statistical analysis of the data involvingcomparisons of the treated and untreatedgroups at baseline and 8–12 weeks wasperformed using the two tailed t test.5 TheWilcoxon signed rank test was used tocompare the individual vision performancefrom baseline to the 8–12 week examination.6

For visual acuity and colour vision, a positiverank indicated improvement and a negativerank indicated a worse visual outcome. Forthe visual field grade, the scale was reversed.Spearman correlation analysis was performedon the time to start therapy and whetherworsening in any visual parameter occurred.7

The mean baseline acuity (0.56, SD 0.30)and visual field (1.9, SD 0.73) for the treated

group was similar to the acuity (0.40, SD 0.41;p=0.22) and field (1.9, SD 0.75; p=0.96) forcontrols. The mean baseline colour vision(0.74, SD 0.4) for the treated group washigher than the colour vision (0.45, SD 0.44)for controls, but the difference was notsignificant (p=0.07). At the 8–12 week exam-ination, the mean visual acuity was 0.29 (SD0.30) for treated and 0.49 (SD 0.39; p=0.12)for untreated patients. The mean visual fieldgrade was 2.2 (SD 0.81) for treated and 1.62(SD 0.70; p=0.04) for untreated patients. Themean colour vision was 0.42 (SD 0.41) fortreated and 0.55 (SD 0.46; p=0.43) foruntreated patients.

For the masked examiner’s evaluation, themean baseline visual field (2.0, SD 0.91) wassimilar to the field (1.93, SD 0.96; p=0.85) forcontrols. At the 8–12 week examination, themean visual field grade was 2.15 (SD 0.99) fortreated and 1.87 (SD 0.92; p=0.43) foruntreated patients. This examiner furtherfound that the outcome visual fields for thetreated group were improved in two patients,worse in six patients (50%), and unchanged infour patients. The outcome visual fields for thecontrol group were improved in five patients,worse in two patients (13%), and unchangedin eight patients.

The Wilcoxon signed rank analysis demon-strated that for visual acuity, two patients inthe control group and 10 patients in thetreated group had negative values or a worseoutcome at 8–12 weeks (p=0.007). For colourvision, one patient in the control group andeight patients in the treated group had nega-tive values or a worse outcome (p=0.013). Forvisual fields, one patient in the control groupand four patients in the treated group hadpositive values or a worse outcome at 8–12weeks (p=0.046).

The average time to start the drops was 3.5days from the onset of visual loss in thosepatients who worsened. There was no correla-tion with a worse outcome and time to initiatetherapy.

For all parameters of vision testing, therewas a trend for worse visual performance at8–12 weeks in the group treated with topicalbrimonidine. Although there was no signifi-cant difference for the colour vision outcome,this might reflect that the baseline colourvision value was better for the treated group.The outcome visual field grade was signifi-cantly worse in the treated group. The maskedexaminer’s visual field evaluations demon-strated that more treated patients worsenedthan in the untreated group. When thebaseline and outcome of all visual parametersfor each individual were compared, thetreated group had a significantly worseoutcome at 8–12 weeks.

Our results are not the first description ofworse outcome in patients treated with α-2agonists for central nervous system ischaemicdisease. Studies in animal models and clinicalstudies in humans suggest that certain classesof drugs, including α-2 receptor agonists, mayimpede recovery following stroke. Clonidineadministration caused recurrence of theneurological deficit in animals who hadinitially recovered. In a retrospective clinicalstudy, the level of motor recovery of strokepatients was worse in those treated with α-2agonists than in patients not receiving theseagents.8

Although in experimental optic nerve in-jury in animal models, brimonidine appearsto offer neuroprotection, our results demon-strate that brimonidine tartrate, applied topi-cally up to four times daily, does not appear tobe a beneficial treatment for acute NAION. It

PostScript 1193




j.com/

Br J O


ugust 2003. Dow

nloaded from

http://bjo.bmj.com/

is possible earlier treatment might have beenmore effective, although patients who wors-ened received treatment sooner than thosewho did not worsen. Increased dosing fre-quency or using a different preparation of bri-monidine might be more effective. Addition-ally, the number of subjects in the study wassmall and a negative trend could appear moreprofound.

H E Fazzone, M J KupersmithThe Institute for Neurology and Neurosurgery, Beth

Israel Medical Center, the New York Eye and EarInfirmary New York, USA

J LeibmannThe New York Eye and Ear Infirmary

Correspondence to: Mark J Kupersmith, MD,Department of Neuro-ophthalmology, Room 535,

The Institute for Neurology and Neurosurgery, BethIsrael Medical Center, 170 East End Avenue, NewYork, NY 10128, USA; [email protected]

Accepted for publication 2 March 2003

References1 Woldemussie E, Ruiz G, Wijono M, et al.

Neuroprotection of retinal ganglion cells bybrimonidine in rats with laser-induced chronicocular hypertension. Invest Ophthalmol Vis Sci2001;42:2849–55.

2 Wheeler LA, Woldemussie E. Alpha-2adrenergic receptor agonists areneuroprotective in experimental models ofglaucoma. Eur J Ophthalmol 2001;11(suppl2):S30–5.

3 Yoles E, Wheeler LA, Schwartz M.Alpha2-adrenoreceptor agonists areneuroprotective in a model of optic nervedegeneration. Invest Ophthalmol Vis Sci1999;40:65–73.

4 Wheeler LA, Gil DW, Woldemussie E. Roleof alpha-2 adrenergic receptors inneuroprotection and glaucoma. SurvOphthalmol 2001;45(suppl 3):S290–4.

5 Fisher LD, Van Belle G. One- and two-sampleinference. In: Biostatistics, a methodology forthe health sciences. Ch 5. New York: JohnWiley, 1993.146–7.

6 Fisher LD, Van Belle G. Nonparametric,distribution-free and permutation models:robust procedures. In: Biostatistics, amethodology for the health sciences. Ch 8.New York: John Wiley, 1993:310–14.

7 Fisher LD, Van Belle G. Association andprediction: linear models with one predictorvariable. In: Biostatistics, a methodology forthe health sciences. Ch 9. New York: JohnWiley, 1993:385–6.

8 Goldstein LB. Potential effects of commondrugs on stroke recovery. Arch Neurol1998;55:454–6.

Chronic eye movement inducedpain and a possible role for itstreatment with botulinum toxinChronic ocular pain may have many causesand can be a frustrating problem for bothpatient and doctor alike. We describe twopatients who had similar symptoms and eyefindings who had been unable to relieve theirpain with conventional analgesia. We postu-late a cause for their pain and describe ourexperience of a treatment strategy using astandard dose of botulinum toxin injectioninto an extraocular muscles.

Case 1A 56 year old white woman presented withwhat was initially thought to be a right orbitalcellulitis but investigations and clinical coursesubsequently suggested a non-infectious idio-pathic inflammatory aetiology. Her historysuggested orbital myositis and she describedright sided facial weakness, nausea, and right

sided ptosis. She had a 9 month course of oralsteroids and despite this needed tramadol,paracetamol, and flurbiprofen to control herpain. Her symptoms and examination find-ings slowly stabilised until she was left withmarked limitation of upgaze in her right eye.Her symptoms did not change over the next 3years, at which point she was referred to ourcare. When she attempted to look up shedescribed a juddering sensation and severepain just above the eye. She rarely had pain atnight but was still using regular oral ibupro-fen for pain relief. Her pain was exacerbatedby reading or looking at the computer and shecomplained of vertical diplopia.

On examination she had limitation ofabduction and elevation of her right eye andprisms did not improve her symptoms. A ten-tative diagnosis of inflammatory spasm wasmade. She was treated with botulinum toxininjection to her right inferior rectus. Twoweeks later there was much less tightness anddiscomfort in the orbit but she had diplopia inall positions of gaze and was forced to occludeone eye. Three months later the pain wasmuch improved but she still found the diplo-pia intolerable and declined further treat-ment.

Case 2A 46 year old white man presented complain-ing of chronic constant ocular discomfortwhich followed strabismus surgery 8 yearsearlier for an A-pattern exotropia with diplo-pia on downgaze. The pain was worsened byprolonged television watching and prisms inhis glasses did not help. Pain was much worseon upgaze and right gaze, which were limited.Oral non-steroidal anti-inflammatory agents(NSAIDs) did reduce the pain a little but onlywhen taken in high doses (100 mg three timesdaily flurbiprofen).

On examination he had a right hyperpho-ria, with an A-pattern esotropia and anabnormal head posture for distance. He stillhad diplopia. Botulinum toxin was injectedinto his left medial rectus muscle, whichresulted in a profound reduction in his symp-toms, leaving him with a small exophoria. Hisdiplopia resolved completely after 10 weeks.The “pressure sensation” and pain in the righteye recurred after about 6 months, this timewith no diplopia. He had a further injection oftoxin 8 months after the first which again sig-nificantly improved his pain but gave himdiplopia for 3 weeks. He continues to takeflurbiprofen 50 mg three times daily orally.

CommentThe pain demonstrated by these two patientsis typically much worse in certain directionsof gaze and particularly during prolongedgaze holding such as when reading or watch-ing television. It had a clear precipitatingevent and the most remarkable feature is thatit had persisted for over 2 years in each casewithout significant progression or regression.No active disease process could be found toaccount for the continued pain. The pain issevere and responds only to high doses ofanalgesics, particularly NSAIDs. None of ourpatients felt that their pain was satisfactorilycontrolled by their analgesics.

We believe that there may be a process ofchronic low grade inflammation affecting theextraocular muscles or the tissues aroundthem which is exacerbated by continued con-traction and relaxation of the same muscles.Muscular spasm perhaps triggered by thisinflammatory process may be the cause of themost severe pain and this could account forthe exacerbations of pain in certain directions

of gaze and on prolonged gaze holding activi-ties. Ocular muscle ischaemia, perhaps causedby constricting scar tissue, remains a possi-bility but the onset of the pain is very fastmaking this less likely.

The pain relief seen in our patients maysimply be the result of paralysing an inflamedmuscle but there is growing evidence for aseparate antinociceptive effect of botulinumtoxin.1 No direct peripheral cutaneous antino-ciceptive effect could be shown by Blersch etal2; however inhibition of release of substanceP has been demonstrated in vitro and it can behypothesised that botulinum toxin treatmentmay reduce the local release of nociceptiveneuropeptides from either cholinergic neu-rons or from C or A delta fibres in vivo.3 Themechanisms by which botulinum toxin mayrelieve pain, including a possible analgesiceffect of botulinum toxin metabolites, arereviewed by Guyer.4

There is a growing literature on the use ofbotulinum for painful conditions,5 particu-larly those in which muscle spasm plays apart. These include writer’s cramp,6 postopera-tive pain in spastic cerebral palsy,7 andperhaps more surprisingly migraine8 andpainful tic convulsif.9 Many of the reporteduses are single case studies and not allcontrolled trials have shown a positive effectof treatment.10

It is not possible to rule out a powerful pla-cebo effect in our patients but, whatever themechanism of action, their pain was vastlyimproved and botulinum toxin treatment isvery safe in competent hands.

In the cases described botulinum toxinserved a dual purpose in that it had thepotential to improve their ocular deviation forwhich it is well known and it also reduced thesevere ocular discomfort. Unfortunately, theresulting diplopia limited its usefulness in onecase but we feel that this treatment should beconsidered in this unusual group of patientswho present a difficult management problemeven to the most experienced ophthalmolo-gists.

B J L Burton, S R Khan, J P LeeMoorfields Eye Hospital, City Road, London, UK

Correspondence to: John P Lee, Moorfields EyeHospital, City Road, London, UK;

[email protected]


References1 Sheean G. Botulinum toxin for the treatment

of musculoskeletal pain and spasm. Curr PainHeadache Rep 2002;6:460–9.

2 Blersch W, Schulte-Mattler WJ, Przywara S,et al. Botulinum toxin A and the cutaneousnociception in humans: a prospective,double-blind, placebo-controlled, randomizedstudy. J Neurol Sci 2002;205:59–63.

3 Aoki KR. Pharmacology and immunology ofbotulinum toxin serotypes. J Neurol2001;248(Suppl 1):3–10.

4 Guyer BM. Mechanism of botulinum toxin inthe relief of chronic pain. Curr Rev Pain1999;3:427–31.

5 Jost WH, Kohl A. Botulinum toxin:evidence-based medicine criteria in rareindications. J Neurol 2001;248(Suppl1):39–44.

6 Turjanski N, Pirtosek Z, Quirk J, et al.Botulinum toxin in the treatment of writer’scramp. Clin Neuropharmacol1996;19:314–20.

7 Barwood S, Baillieu C, Boyd R, et al.Analgesic effects of botulinum toxin A: arandomized, placebo-controlled clinical trial.Dev Med Child Neurol 2000;42:116–21.

1194 PostScript




j.com/

Br J O


ugust 2003. Dow

nloaded from

http://bjo.bmj.com/

8 Gobel H, Heinze A, Heinze-Kuhn K, et al.Evidence-based medicine:botulinum toxin A inmigraine and tension-type headache. J Neurol2001;248(Suppl 1):34–38.

9 Micheli F, Scorticati MC, Raina G. Beneficialeffects of botulinum toxin type A for patientswith painful tic convulsif. ClinNeuropharmacol 2002;25:260–2.

10 Wheeler AH, Goolkasian P, Gretz SS.Botulinum toxin A for the treatment of chronicneck pain. Pain 2001;94:255–60.

Intrastromal lamellarfemtosecond laser keratoplastywith superficial flapLamellar keratoplasty has usually been per-formed taking a trephine to delineate theextent of the tissue to be excised, and a knifeor similar instrument to remove the lamellarcorneal tissue from the underlying deepcorneal bed. In a similar way, the lamellardonor tissue was prepared and inserted intothe recipient bed. The depth of the lamellarexcision extended from the corneal epithelialsurface to the deep corneal stroma. Markeddisadvantages of the technique have beenpronounced corneal astigmatism and opticalinsufficiencies of the interface between thelamellar graft and the recipient corneal bedcaused by irregularities of both surfaces. Thepurpose of the present report was to describethe new femtosecond laser technology,1–3

which may enable us to perform a new type ofintrastromal lamellar keratoplasty with pres-ervation of an intact Bowman’s layer andregular corneal epithelium.

Case reportUsing a corneal contact lens and a femtosec-ond laser (20/10 Perfect Vision, Am Tauben-feld 21/1, D-69123 Heidelberg, Germany) witha wavelength of 1060 nm, a spot size of about10 µm, and a laser pulse duration of severalhundred femtoseconds, a pre-descemetal inci-sion running parallel to the corneal surfacewas created in five postmortem eyes ofslaughterhouse pigs. The diameter of the deepstromal incision was 7 mm. In a second step,a circular sagittal incision was performedstarting from the peripheral edge of thealready existing incision in the pre-descemetal level to the superficial layer of thecorneal stroma. In continuation of the lattersagittal incision, a corneal flap was preparedwith a diameter of 7 mm, a thickness of about100 µm, a hinge, and three positional pikes.4

The pikes in the flap with the correspondingnotches in the bed of the flap were formed toincrease the rotational stability of the flapafter repositioning. The height of the peakswas about 0.40 mm. After opening of the flapthe intrastromal segment situated betweenthe pre-descemetal incision and the incisionin the superficial stromal level was removedand exchanged against a similar formedsegment obtained from another (donor) pigeye. In a final step, the flap was repositioned.

For all eyes included in the study, theintrastromal corneal button and the superfi-cial flap with the three positional pikes couldbe prepared without major difficulties. Thecorneal buttons could easily be repositionedinto their original beds as well as into therecipient beds of other eyes in which therecipient beds were created with the samediameter as the donor button. The time takenfor preparation of the intrastromal cornealbutton and the corneal flap, and for theexchange of the corneal buttons was less than10 minutes in all cases.

CommentFemtosecond laser technology allows a newtype of intrastromal lamellar keratoplasty

with removal of a mid-stromal segment andpreservation of an intact Bowman’s mem-brane. Considering the decreased amount ofallogenic corneal tissue transplanted, andregarding the preservation of the original cor-neal surface, lamellar intrastromal femtosec-ond laser keratoplasty may be associated witha smaller rate of immunological graft reactionand with a lower postoperative corneal astig-matism in some eyes. Future clinical studiesmay show whether positional edges in thesuperficial flap increase its postoperative rota-tional stability.

Proprietary interest: none

J B JonasUniversitäts-Augenklinik, Theodor-Kutzer-Ufer 1–3,

68167 Mannheim, Germany;[email protected]


References1 Stern D, Schoenlein RW, Puliafito CA, et al.

Corneal ablation by nanosecond, picosecond,and femtosecond lasers at 532 and 625 nm.Arch Ophthalmol 1989;107:587–92.

2 Krueger RR, Quantock AJ, Juhasz T, et al.Ultrastructure of picosecond laser intrastromalphotodisruption. J Refract Surg1996;12:607–12.

3 Kurtz RM, Horvath C, Liu HH, et al. Lamellarrefractive surgery with scanned intrastromalpicosecond and femtosecond laser pulses inanimal eyes. J Refract Surg 1998;14:541–8.

4 Seitz B, Langenbucher A, Kus MM, et al.Nonmechanical corneal trephination with theexcimer laser improves outcome afterpenetrating keratoplasty. Ophthalmology1999;106:1156–64; discussion 1165.

Demographic study of paediatricallergic conjunctivitis within amultiethnic patient populationFrom October 1999, all patients referred to thepaediatric ophthalmology service in Bradfordhave been added to a computerised database.This is the only paediatric ophthalmologyservice within the city of Bradford andreceives all GP referrals of this type. Patientswith a clinical diagnosis of chronic allergicconjunctivitis were identified from October1999 to July 2001. We compared the relativeprevalence of chronic allergic eye diseasebetween white and Asian patients in the pae-diatric population of the city of Bradford.

Confirmation of the diagnosis of chronicallergic conjunctivitis was made using caserecords. All patients were seen at the first visitby a consultant paediatric ophthalmologist(JAB).

A diagnosis of chronic allergic conjunctivi-tis was made if the patient had characteristicsymptoms and signs based on criteria set outby Buckley in 1998.1 This was done to ensureaccurate and consistent diagnosis of chronicallergic conjunctivitis so as not to includeother forms of ocular allergy—for example,drug allergy or preservative toxicity. Inclusioncriteria required a history of at least three ofthe following: a history of recurring symp-toms over a period of at least 1 year; itching asa symptom; personal or family history of non-ocular allergic disease; and exacerbation dur-ing the pollen season and/or exposure tohousehold pets. Presence of the followingclinical signs was also necessary—conjunctival hyperaemia and subtarsal papil-lae.

Patients were excluded if they had anysigns of staphylococcal blepharoconjunctivitissuch as eyelid and eyelash crusting; matting

of the eyelids; purulent, sticky discharge; eye-lid notching and scarring. Patients withmixed disease were also excluded from thisstudy. The presence of corneal complicationsthat required topical steroid for resolution wasused to define severe disease.

Clinical dataForty three patients were identified from thedatabase; 39 patients fulfilled entry criteriafor this study and records were retrieved for35. There were 24 Asians and 11 whitechildren.

For Asian patients, the mean age was 9.58(SD 4.02) years. For the white patients, themean age was 7.82 (SD 3.19) years,. Follow upranged from 3–14 months, mean 6 months.The prevalence of allergic conjunctivitis inAsians was 59 per 100 000 (24 in 40 524) andin white children, 12 per 100 000 (11 in93 398); a relative prevalence of 5 to 1 (χ2 testp <0.001).

There was a predominance of males in bothethnic groups, 2.4:1 in Asians and 1.8:1 inwhite children. This difference in sex was notsignificant between both groups (Fisher’s test,p=0.71).

The overall age distribution for all maleswas 8.54 years and for all females was 10.01years. For Asians, the mean age for males was9.18 years and for females was 10.57 years. Forwhite children, the mean age for males was7.00 years and for females was 9.25 years.

Corneal complicationsThere were 14 with punctate epithelial ero-sions (10 Asians and four white children).Comparing patients from both groups withsevere disease, there was a relative prevalenceof Asians by 6.75 to 1 (Fisher’s test, p=0.001).

In two cases, visual loss occurred after theonset of chronic allergic conjunctivitis fromepithelial plaque and corneal pannus. Bothwere Asian.

CommentVarious studies have reported allergic eye dis-ease to be more common among Asian andblack patients.2–4 This may be due to geneticand/or environmental factors.4–10

We found allergic eye disease to be morecommon in Asians than white children. It ispossible that ocular allergy is multifactorialbut perhaps with a greater genetic predisposi-tion in certain ethnic communities.11 We couldnot comment on the prevalence of chronicallergic conjunctivitis in the community be-cause of referral bias since we only seepatients referred by GPs. The extent to whichmilder cases are treated in the community isnot known but we feel that the more severecases are the ones referred to our department.

Our findings highlight that allergic eye dis-ease appears to be more common and compli-cated in Asian patients in the Bradford popu-lation. This potential risk of sight threateningdisease means that they are more likely torequire topical steroid treatment. This has ledus to recognise that appropriately aggressivetreatment is essential in these patients.

A J Singh, R S K Loh, J A BradburySt James’s University Hospital, Becket Street, Leeds

LS9 7TF, UK

Correspondence to: Mr Anil J Singh, St James’sUniversity Hospital, Becket Street, Leeds LS9 7TF,

UK; [email protected]


References1 Buckley RJ. Allergic eye disease-a clinical

challenge. Clin Exp Allergy 1998;28(Suppl6):39–43.

PostScript 1195




j.com/

Br J O


ugust 2003. Dow

nloaded from

http://bjo.bmj.com/

2 Spraul CW, Lang GK. Allergic and atopicdiseases of the lid, conjunctiva and cornea.Curr Opin Ophthalmol 1995;6:21–6.

3 O’Shea JG. A study of vernalkeratoconjunctivitis and othereosinophil-mediated external eye diseasesamongst Palestinians. Ophthalmic Epidemiol2000;7:149–57.

4 Montan PG, Ekstrom K, Hedlin G, et al.Vernal keratoconjunctivitis in a Stockholmophthalmic centre-epidemiological, functional,and immunologic investigations. ActaOphthalmol Scand 1999;77:559–63.

5 Belfort R, Marbeck P, Hsu C, et al.Epidemiological study of 134 subjects withallergic conjunctivitis. Acta Ophthalmol Scand2000;78:38–40.

6 Tabbara KF, Butrus SI. Vernalkeratoconjunctivitis and keratoconus. Am JOphthalmol 1983;95:704–5.

7 Totan Y, Hepsen IF, Cekic O, et al. Incidenceof keratoconus in subjects with vernalkeratoconjunctivitis: a videokeratographicstudy. Ophthalmology 2001;108:824–7.

8 Aberg N. Familial occurrence of atopicdisease: genetic versus environmental factors.Clin Exp Allergy 1993;23:829–34.

9 Dotterud LK, Kvammen B, Bolle R, et al. Asurvey of atopic diseases among schoolchildren in Sor-Varanger community. Possibleeffects of subarctic climate and industrialpollution from Russia. Acta Derm Venereol1994;74:124–8.

10 Freissler KA, Lang GE, Lang GK. Allergicdiseases of the lids, conjunctiva, and cornea.Curr Opin Ophthalmol 1997;8:25–30.

11 Angioni AM, Fanciulli G, Corchia C.Frequency of and risk factors for allergy inprimary school children: results of apopulation survey. Paediatr Perinat Epidemiol1989;3:248–55.

CORRECTION

We wish to apologise for an error in theextended report by Barry and König (Br JOphthalmol 2003;87:909–16). On p 910 underthe heading Orthoptic screening, point four ofthe bulleted list, line four should have read:“positive”: visual acuity <0.4 (10/25).

NOTICES

Helping the blind and visuallyimpairedThe latest issue of Community Eye Health (No45) discusses help for the blind, with aneditorial by Sir John Wall of the RoyalNational Institute for the Blind on the rightsof blind people. For further informationplease contact: Journal of Community EyeHealth, International Resource Centre, Inter-national Centre for Eye Health, Department ofInfectious and Tropical Diseases, LondonSchool of Hygiene and Tropical Medicine,Keppel Street, London WC1E 7HT, UK(tel: +44 (0)20 7612 7964; email:[email protected]; website: www.jceh.co.uk). Annual subscription (4 issues)UK£28/US$45. Free developing country appli-cants.

Second SightSecond Sight, a UK based charity whose aimsare to eliminate the backlog of cataract blindin India by the year 2020 and to establishstrong links between Indian and British oph-thalmologists, is regularly sending volunteersurgeons to India. Details can be found at thecharity’s website (www.secondsight.org.uk)or by contacting Dr Lucy Mathen([email protected]).

SPecific Eye ConditionS (SPECS)SPecific Eye ConditionS (SPECS) is a not forprofit organisation which acts as an umbrellaorganisation for support groups of any condi-tions or syndrome with an integral eye disor-der. SPECS represents over 50 differentorganisations related to eye disorders rangingfrom conditions that are relatively common tovery rare syndromes. The website acts as aportal giving direct access to support groupsown sites. The SPECS web page is a valuableresource for professionals and may also be ofinterest to people with a visual impairment orwho are blind. For further details aboutSPECS contact: Kay Parkinson, SPECS Devel-opment Officer (tel: +44 (0)1803 524238;email: [email protected]; website:www.eyeconditions.org.uk).

The British Retinitis PigmentosaSocietyThe British Retinitis Pigmentosa Society(BRPS) was formed in 1975 to bring togetherpeople with retinitis pigmentosa and theirfamilies. The principle aims of BRPS are toraise funds to support the programme ofmedical research into an eventual cure for thishereditary disease, and through the BRPSwelfare service, help members and their fami-lies cope with the everyday concerns causedby retinitis pigmentosa. Part of the welfareservice is the telephone help line (+44(0)1280 860 363), which is a useful resourcefor any queries or worries relating to theproblems retinitis pigmentosa can bring. Thisservice is especially valuable for those recentlydiagnosed with retinitis pigmentosa, and allcalls are taken in the strictest confidence.Many people with retinitis pigmentosa havefound the Society helpful, providing encour-agement, and support through the Help line,the welfare network and the BRPS branchesthroughout the UK (tel: +44 (0)1280 821 334;email: [email protected]; website:www.brps.demon.co.uk).

Surgical Eye ExpeditionsInternationalVolunteer ophthalmologists in active surgicalpractice are needed to participate in shortterm, sight restoring eye surgery clinicsaround the world. Contact: Harry S Brown,Surgical Eye Expeditions International, 27East De La Guerra, C-2, Santa Barbara, CA93101–9858, USA (tel: +805 963 3303; fax:+805 965 3564; email: [email protected] [email protected]; website: www.seeintl.org).

Rise in organ transplantnumbersAccording to UK Transplant, the UK has seenthe highest number of organ transplants insix years. Last year (1 April 2002 to 31 March2003) 2777 patients had their lives saved ordramatically improved through the generosityof 1064 donors. This equated to a 6% increasecompared to the previous 12 months (1 April2001 to 31 March 2002). Furthermore during2002–3, the highest number of people ben-efited from a cornea transplant for five years(1997–98) and 240 more people had theirsight restored than the previous year. For fur-ther information see UK Transplant’s website(www.uktransplant.org.uk).

Elimination of avoidableblindnessThe 56th World Health Assembly (WHA) con-sidered the report on the elimination of

avoidable blindness (doc A56/26) and urgedMember States to: (1) Commit themselves tosupporting the Global Initiative for the Elimi-nation of Avoidable Blindness by setting up anational Vision 2020 plan by 2005; (2) Estab-lish a national coordinating committee forVision 2020, or a national blindness preven-tion committee to help implement the plan;(3) Implement the plan by 2007; (4) Includeeffective monitoring and evaluation of theplan with the aim of showing a reduction inthe magnitude of avoidable blindness by2010; (5) To support the mobilisation ofresources for eliminating avoidable blindness.The WHA also urged the Director-General tomaintain and strengthen WHO’s collabora-tion with Member States and the partners ofthe Global Initiative for the Elimination ofAvoidable Blindness as well as aid in the coor-dination and support of national capability.

MSc course in Community EyeHealthThe International Centre for Eye Health isoffering a full time MSc course in CommunityEye Health from 29 September 2003 to 19September 2004. The course is not clinical andis specifically for eye health professionalswanting to work in the field of community eyehealth. The course is designed in keeping withthe aims, priorities, and strategies of Vision2020—the Right to Sight. The course costs£3939 for home students and £14 110 foroverseas students. Further information: TheRegistry, 50 Bedford Square, LondonWC1B 3DP, UK (tel: +44 (0)20 7927 2239;fax: +44 (0)20 7323 0638; email:[email protected]; website:www.lshtm.ac.uk).

Ophthalmic Anesthesia Society(OAS)—17th Scientific MeetingThe 17th Scientific Meeting of the Ophthal-mic Anesthesia Society (OAS) will be held 3–5October 2003 at the Westin Michigan AvenueChicago, Chicago, USA. Programme co-chairs:Marc Allen Feldman MD MHS and Steven TCharles MD. The CME joint sponsor is theCleveland Clinic Foundation; CME hours arepending. Fees for OAS members are $300;non-members $475; students $50.Further details: OAS, 793-A Foothill Blvd,PMB 119, San Luis Obispo, CA 93405 USA(tel: +1 805 534 0300; fax: +1 805 534 9030;email: [email protected]; website:www.eyeanesthesia.org).

Glaucoma Society 24th AnnualMeeting and DinnerThe Glaucoma Society 24th Annual Meetingand Dinner will take place on 20 November2003, from 8:30 am to 5:00 pm at The RoyalCollege of Physicians, London, UK. Furtherdetails: Ms Janet Flowers (email:[email protected]).

Detachment Course withinternational faculty on: Retinaland Vitreous Surgery with CasePresentations preceding theAnnual Meeting of IranianSociety of OphthalmologyThe detachment course with international fac-ulty on: Retinal and Vitreous Surgery with CasePresentations preceding Annual Meeting ofIranian Society of Ophthalmology will be held

1196 PostScript




j.com/

Br J O


ugust 2003. Dow

nloaded from

http://bjo.bmj.com/

on 29–30 November 2003 and 1–4 December

2003 respectively, at the Razi Conference

Center, Hemmat Hyw, Tehran, Iran. Further

details: Scientific programme: Prof Ingrid Kre-

issig, University of Tuebingen, Schleichstr. 12,

Breuningerbau, 72076 Tuebingen, Germany

(tel: +49 7071 295209; email:

[email protected]). Local

organisation: Dr Arman Masheyekhi, Dr Sia-

mak Moradian, Dept of Ophthalmology, Lab-

banfinejad Medical Center, Pasdaran Ave,

Boostan 9, Tehran, 16666, Iran (fax: +98 21 254

9039; email: [email protected]).

5th International Symposium onOcular Pharmacology andTherapeutics (ISOPT)

The 5th International Symposium on OcularPharmacology and Therapeutics (ISOPT) willtake place 11–14 March 2004, in Monte Carlo,Monaco. Please visit our website for details ofthe scientific programme, registration, andaccommodation. To receive a copy of the Callfor Abstracts and registration brochure pleasesubmit your full mailing details to http://www.kenes.com/isopt/interest.htm.

Further details: ISOPT Secretariat (website:www.kenes.com/isopt).

XVth Meeting of theInternationalNeuro-Ophthalmology SocietyThe XVth Meeting of the International Neuro-Ophthalmology Society will take place 18–22July 2004, in Geneva, Switzerland.Further details: Prof. A Safran, UniversityHospital Geneva, c/o SYMPORG SA,Geneva (fax: +4122 839 8484; email:[email protected]; website: www.symporg.ch).

PostScript 1197




j.com/

Br J O


ugust 2003. Dow

nloaded from

http://bjo.bmj.com/

87 PostScript - bjo.bmj.com · ated with a poor visual prognosis.5 In a small study CNV was...

Documents

Transcript of 87 PostScript - bjo.bmj.com · ated with a poor visual prognosis.5 In a small study CNV was...